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AMI Acute myocardial infarction 
BMI Body mass index 
CABG Coronary artery bypass graft 
CRT-P Cardiac resynchronization pacemaker (“biventricular pacemaker”) 
CRT-D Cardiac resynchronization pacemaker with implantable cardioverter 
defibrillator 
CVD Cardiovascular disease 
DALY Disability-adjusted life year 
EHRA European Heart Rhythm Association 
ESC European Society of Cardiology 
EUROASPIRE European Action on Secondary Prevention through Intervention to 
Reduce Events 
FAO Food and Agriculture Organization of the United Nations 
GBD Global burden of disease 
GDP Gross domestic product 
GNI Gross national income 
ICD Implantable cardioverter-defibrillator 
IHD Ischaemic heart disease 
IHME Institute for Health Metrics and Evaluation 
IQR  inter-quartile range 
NCD-RisC Noncommunicable Diseases Risk Factor Collaboration 
NCS National cardiac societies 
PCI Percutaneous coronary intervention 
PPP Purchasing power parity 
PYLL Potential years of life lost 
TAVI Transcatheter aortic valve implantation 
UK United Kingdom 
USA United States of America 
WB World Bank 





Risk factors and lifestyle 
 Across ESC member countries, almost one in four people had raised blood pressure. 
Systolic blood pressure was higher in men compared with women and in middle-income 
compared with high-income countries 
 More than one in 20 adults had diabetes with prevalence lower in high-income compared 
with middle-income countries. Prevalence has increased three-fold the last 25 years. 
 Age standardised data showed that one in four adult women and men were obese 
 More than one in five adults were smokers. Smoking was more common in men than 
women. In middle-income countries nearly half of adult men smoked compared with 10% 
of women. 
 Alcohol consumption was more than three times higher in men compared with women 
and almost twice as high in high-income compared with middle-income countries 
 Physical activity was graded insufficient in one in three adults. Rates of inactivity were 
somewhat higher in women compared with men and in high-income compared with 
middle-income countries. 
CVD morbidity and mortality 
 Across ESC member countries, the age-standardised incidence of ischaemic heart disease 
(IHD) and stroke, have shown a downward trend during the last 27 years. 
 The age-standardised incidence and prevalence of IHD and stroke were lower in women 
compared with men and in high-income compared with middle-income countries. 
 Disability-adjusted life years (DALYs) lost to CVD were almost twice as high in men 
compared with women and three times as high in middle-income compared with high-
income countries. 
 Despite sustained declines in CVD mortality in many countries across Europe, it has 
remained the most common cause of death. 
 CVD was also the most common cause of premature (age <70 years) death among men but 
in women cancer was the bigger killer 
 CVD accounted for 34% of potential years of life lost (PYLLs) for men and 37% for women. 
In comparison, cancer accounts for 22% of PYLLs in men and 25% in women 
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 For women in middle income countries a median of 35% of all premature deaths were 
caused by CVD compared with 16% in high income countries. For men the respective rates 
were 36% in middle income countries compared with 24% in high income countries. 
CVD healthcare delivery 
 Compared with high income countries, middle income countries are severely under-
resourced in terms of cardiological person-power and technological infrastructure 
 Middle-income countries suffer a severe procedural deficit compared with high-income 





This is the second report on cardiovascular disease (CVD) statistics for the 56 member 
countries of the European Society of Cardiology (ESC). It updates and expands upon the 2017 
report which has been widely cited by researchers and other stakeholders during the two 
years since its publication.1 The CVD statistics that constitute these reports are drawn from 
the ESC Atlas that is compiled and regularly updated by the European Heart Agency in 
Brussels. 2  The Atlas is a repository of CVD data collected by groups such as the World Health 
Organisation, the Institute for Health Metrics and Evaluation and the World Bank. It also 
includes novel ESC sponsored data on human and capital infrastructure and cardiovascular 
healthcare delivery obtained by annual survey of the national societies of ESC member 
countries. 
 
The 2019 report, like its predecessor, includes chapters on risk factors and health behaviours, 
CVD morbidity and mortality and cardiovascular healthcare delivery across the ESC member 
countries. The chapters have been updated with presentation of latest available disease 
statistics and also expanded to include a broader range of CVD phenotypes and additional 
information about human and capital resources and interventional treatments. Again, much 
attention has been given to the inequalities that exist between high-income and middle-
income ESC member countries which have shown little sign of diminishing in the last two 
years. Inequalities affect both disease prevalence and healthcare delivery which vary 
according to the predictions of Tudor Hart’s inverse care law.3 The causes of these inequalities 
are complex but economic context is clearly an important factor which now receives further 
attention in a new chapter on the cardiovascular healthcare economics of selected ESC 
member countries.  
 
The 2019 report also provides a focus on the WHO non-communicable disease (NCD) targets 
relevant to global cardiovascular health.4 The targets call for  reductions in CVD mortality and 
risk factors with reference to 2010 as follows: 
 a 25% reduction in CVD mortality 
 a 10% reduction in harmful use of alcohol 
 a 10% reduction in prevalence of insufficient physical activity 
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 a 30% reduction in mean population intake of salt 
 a 30% reduction in current tobacco use 
 a 25% reduction in prevalence of raised blood pressure 
 a halt to the rise of diabetes and obesity 
 drug therapy to prevent heart attack and stroke in 50% of eligible people 
The deadline for meeting these targets is 2025 and the progress being made by ESC member 
countries is summarised in relevant sections of this report. 
 
This report of cardiovascular statistics for ESC member countries responds to WHO 
recommendations for development of surveillance and monitoring programmes in order to 
understand the international distribution of CVD, and predict future trends (5).5 It provides 
an essential resource to guide national policy directives aimed at reducing the burden of CVD 
according to the mission statement of the ESC. 
 
 
2. Data sources and presentation 
 
Key data sources for the European Society of Cardiology Atlas include: 
 European Society of Cardiology (ESC): statistics on national cardiovascular 
infrastructure and procedures derived from a survey of the National Cardiac Societies 
of 41 ESC member countries. 
 World Health Organisation (WHO): risk factor and mortality statistics. 
 Institute for Health Metrics and Evaluation (IHME): morbidity and disease burden 
statistics from the Global Burden of Disease study.  
 World Bank (WB): economic indicators. 
 Food and Agriculture Organization of the United Nations (FAO): dietary data  
2.1 ESC Atlas of Cardiology Data  
The Atlas contains more than 100 variables relating to human and capital infrastructure and 
major cardiovascular interventions and services from 41 ESC member countries.2 Specific 
variables developed by a task force were included in a questionnaire circulated to the national 
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cardiac societies (NCS) of participating ESC member countries. The data collected were then 
subjected to quality control procedures, including comparison with other data sources to 
identify outliers and illogical values. These values were then discussed with the source NCS 
and corrected where necessary. The data were reviewed by independent experts before final 
approval by the NCS. All original data sources were recorded for tracking purposes. 
 
The survey yields absolute numbers for resources and procedures. Crude rates per million 
people are computed from WB population estimates. 6  
 
2.2 World Health Organisation Data  
Mortality data come from the WHO Mortality Database 7 using the May 2018 update of age- 
and cause-specific mortality data by country. These data are publically available. This 
manuscript presents mortality data for 51 of the 56 ESC member countries, all from the WHO 
European Region. No data are presented for Albania, Algeria, Lebanon, Libya or  Republic of 
Kosovo.  
 
The WHO database collates data on the absolute number of medically-certified deaths from 
national authorities based on their vital registration systems. From these primary data, 
mortality rates are calculated using country-level data on population size, obtained from the 
same database, as denominators. Age-standardised rates are computed using the direct 
method with the 2013 European Standard Population (ESP) to control for cross-national 
differences in population age structures.  The 2013 ESP was developed as an update to the 
1976 ESP by the European Commission for the EU27 and European Free Trade Association 
countries to better reflect the age structure of the current European population.   
 
The data presented in the WHO Mortality Database and in this manuscript are as submitted 
by individual countries to WHO. No adjustments have been made to account for potential 
bias in reporting. As a result, the quality of mortality data varies between countries, with more 
accurate data for countries with well-functioning vital registration systems compared with 
those with weaker systems. Even for countries with strong vital registration systems, 
however, regional patterns of clinical diagnosis may reduce cross-country comparability.   
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In general, the mortality data are up-to-date, with the most recent data for only six of the 51 
countries dating from 2013 or before. However, in some cases, individual countries are yet to 
provide their most recent statistics, with the result that the information obtained from the 
WHO might not be as up-to-date as that available from the databases of these individual 
countries.  
 
National data on metabolic/biological risk factors are derived from the WHO and  
Noncommunicable Diseases Risk Factor Collaboration (NCD-RisC) and are based on 
aggregated population data. Estimates are age-standardized to facilitate international 
comparisons. Details of methods and data sources are described elsewhere. 8 9 10 National 
physical activity data come from surveys presenting sex- and age-specific estimates relating 
to WHO activity recommendations, with regression modelling to determine levels of 
insufficient activity.   
 
2.3 Global Burden of Disease - Institute for Health Metrics and Evaluation Data  
Estimates of CVD prevalence come from the Global Burden of Disease study, conducted by 
the Institute for Health Metrics and Evaluation (IHME)11. The estimates are derived using 
modelling software and data from health surveys, prospective cohorts, health system 
administrative data, and registries. 12 13 The GBD study also provides estimates of disability 
adjusted life years (DALYs) from estimates of years living with CVD and years of life lost. The 
accuracy of modelled estimates is heavily dependent on the original data used. This can be a 
challenge where only sub-national, or small sample data are available, or in instances in which 
recent data have not been collected. Such estimates are, therefore, open to concerns 
regarding accuracy when describing the national level burden of CVD. It is also possible that 
current estimates may change, as more recent data become available. 
 
2.4 World Bank Data  
Data on various economic indicators come from the World Bank (WB).14 These data are drawn 
from official sources and in converting estimates of gross national income (GNI) and GNI per 
capita from national currencies to U.S. dollars. The WB uses the Atlas conversion factor to 
help reduce the impact of exchange rate fluctuations in the cross-country comparison of 
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national incomes. The WB also provides national population data which were used for 
calculating rate estimates for ESC member countries. 
 
2.5 Data Presentation and Analysis 
Data from the Atlas are presented for 56 ESC member countries, stratified according to 2018 
World Bank definitions of income status: (Figures 2.1 and 2.2)  
o High-income: GNI per capita US$ ≥12,376 in 2018 
o Upper-middle income GNI per capita US$ 3,896 - 12,375 
o Lower-middle income GNI per capita US$ 996 - 3,895 
Throughout the manuscript the term “middle-income countries” represents a composite of 
upper- and lower-middle income ESC member countries. Data presentation is descriptive, 
illustrated by tables and charts from the ESC Atlas, with only limited interpretation in the 
short commentary paragraphs at the end of each section. No attempt is made to attach 
statistical significance to differences observed in stratified analyses and there is no 
assumption of causation when associations are identified. For consistency, averaged statistics 
across groups of countries are presented as medians in the manuscript.  Box plots were used 
almost exclusively for comparison of CVD statistics between high-income and middle-income 
ESC member countries. The plots display a box representing median values and first and third 
quartile values, with whiskers positioned at the furthest data points within 1.5 times the 
interquartile range. Any countries outside this range are defined as outliers and are plotted 
individually.   
 
2.6 Limitations  
Much of the data in the Atlas are from the WHO, IHME and World Bank which together 
constitute the most credible sources of national estimates of CVD and associated risk factors. 
The validity of the statistics these sources provide is a function of the procedures applied in 
their collection which can be reviewed in the source addresses provided throughout the 
manuscript in the relevant section headings. General limitations of the data include the 
adjustment applied by all the main providers to account for missing data, and differences in 
reporting practices such that precision of the estimates they provide often varies by country. 
Misclassification bias due to miscoding of diagnostic groups and death certificates is another 
potential limitation. Data completeness is clearly defined within each section of the 
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manuscript and for most indicators exceeds 80% although it is lower for diabetes in adults 
(75%), overweight and obesity in children (56%), smoking in children (64%) and physical 
activity in adults (64%) and children (68%). There is also variably missing data in some of the 
time-series collections, indicated by blank cells within the relevant tables, such that in some 
cases our analysis has had to be restricted to patients with data entries at the start, middle 
and final date of the series. National cardiovascular infrastructure and procedure data are at 
present available for only 41 (73%) of ESC member countries.  The Atlas does not provide 
information about within-country inequalities.15 16 Moreover, inequalities between World 
Bank classified high- and middle-income countries are determined by comparing national 
medians averaged across the groups, which obscures within-category inequalities. The 
presentation of minimum and maximum statistics around group medians helps mitigate this 
issue. 
 
The limitations as they apply to the quality, precision and availability of the data emphasise 




3. Financial and economic burden of cardiovascular diseases in ESC 




This chapter aims to shed light on available evidence concerning economic and financial 
burden of cardiovascular diseases in ESC countries. It complements the present manuscript 
on cardiovascular statistics stemming from the ESC Atlas project to highlight the weight 
cardiovascular diseases pose on the healthcare system and societies. We provide estimates 
disaggregated according to the initial classifications of countries in the high and middle-
income group. 
We report the general healthcare expenditure across 56 ESC countries, both in terms of 
absolute values as well as % of GDP. The available resources for financing all healthcare 
services impact those dedicated to cardiovascular care and services. 
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We also provide empirical evidence on both the financial and economic burden of CVD. Given 
the limited availability of comparative international studies, we can only do this in a subset of 
56 countries belonging to ESC. Financial and economic costs are different, despite some 
overlap in the underlying data. Financial costs capture the financial transactions in the system 
which represent expenditure data. In contrast, economic costs capture the value of all 
resources consumed by CVD, both within the health sector and beyond. This financial burden 
is commonly estimated from the perspective of the healthcare sector, while economic 
analysis adopts a broader, societal perspective.  
In this chapter, we initially focus on the financial burden of CVD and present few international 
efforts that have developed methodologies to allocate total health expenditure to CVD to 
allow systematic comparative evidence across countries. Then, we give insights into the social 
and economic burden of CVD based on the very few international studies available at present. 
In the final section, we provide a commentary on the available data and make suggestions on 
future actions to close the critical evidence gap to inform health policies on the allocation of 
healthcare resources in ESC countries.  
 
3.2. Health expenditure across ESC countries  
Data: Gross Domestic Product, Current health expenditure per capita  
Data source: World Bank 
Completeness: all ESC countries  
Year of data: 2000-2016 
,  
Complex interactions between a range of institutional factors, funding arrangements, social 
and economic factors as well as political and cultural values impact on the total amount of 
resources spent on health and healthcare. The total amount of income available in a country, 
commonly measured by GDP, is the key driver behind these interactions. 
Current Health Expenditure (CHE) reflects the total consumption of healthcare goods and 
services, public health and prevention programmes. To allow meaningful comparison across 
countries, first countries' health expenditures are converted to a common currency unit. Then 
these are adjusted to take into account the different purchasing power of national currencies. 
  
Considering 56 countries in our sample with very different types of healthcare systems, 
institutional contexts and income levels, it is not surprising to observe a significant variation 
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in the level of CHE per capita across our sample. Nonetheless, even if expected, the 
differences are striking.  
 
Taking all ESC countries as a whole, per capita health spending averaged to 2619 USD in 2016, 
ranging from as low as approximately 240 USD in Kyrgyzstan to almost 7900 USD in 
Switzerland.  Even after adjusting for local purchasing power, high-income countries spent on 
average four times more on healthcare than those in the lower-middle-income group (USD 
3769 vs 921, respectively). Even within the high-income group, the range was vast (Figure 
3.1). Countries that spent the most on health are Switzerland, Luxemburg and Norway with 
USD 7867, 6374 and 6203 respectively, followed by Germany and Ireland (USD 5436 and 
5299). Middle-income countries that spent the most are Bulgaria, Russia and Serbia (USD 
1577,1329 and 1322) while Morocco and Kyrgyzstan are at the bottom of the list (USD 465 
and 240, respectively) (Figure 3.1) 
 
The ratio of CHE  to GDP is an indicator of how much a country spends on healthcare in 
relation to all other goods and services.  This ratio is used to allow a more meaningful 
comparison across countries in terms of their capacity to finance the healthcare sector.  
Across ESC countries, there are significant variations to be observed also regarding the 
portion of GDP dedicated to the healthcare sector (Figure 3.1). In 2016, all 56 countries put 
together dedicated, on average, 7.89% of GDP to health and healthcare. Among the ESC high-
income countries, an average of 8.62% of GDP was allocated to healthcare in comparison to 
just about 6.84% of GDP in middle income. However, there was much variation within the 
groups. In 2016, high-income countries spent between 6.16% and 12.2% of their GDP for 
healthcare while the range in the middle-income group was even more extensive with almost 
a triple difference between the minimum and maximum value: from 3.53% to 9.92%. Within 
the middle-income group, four countries (Kazakhstan, Turkey, Egypt and Romania) spent less 
than 5% of their GDP on healthcare sector (Figure 3.1).   
 
Among the high-income group, 9 out of 31 countries had spent on health higher than 10% of 
GDP with Switzerland, France and Germany on the top of the list. At the other end of the scale 
within the same income group, seven countries (out of 31) spent less than 7% of their GDP 
on healthcare in 2016 including Estonia, Lithuania, Latvia and Luxembourg. Luxembourg is an 
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example of a high-income country with one of the highest per capita spending across all ESC 
countries (USD 6381 in 2016). However, Luxembourg also has the lowest share of health 
expenditure relative to GDP, which reflects a high level of economic growth.  This example 
demonstrates that we need to consider both absolute and relative healthcare expenditure. 
 
Figure 3.2 shows that after several years of slow health spending growth it appears that 
growth rates in terms of % of GDP dedicated to the health sector have started to pick up again 
between 2012 and 2016. In other words, in the majority of ESC countries, the long-term 
growth in health expenditure per capita has been higher than the growth rate in GDP resulting 
in increasing % of GDP dedicated to health over time. The trend appears to be familiar to both 
high and middle-income ESC countries.  
 
 
3.3. Financial burden of cardiovascular diseases   
Estimating the financial burden of disease with health expenditure data has a very long 
tradition in health economics. A seminal paper was “Estimating the cost of illness” by Dorothy 
Rice.17 This methodological approach is a rather simple one: it is a top-down method that 
allocates total healthcare expenditure at a country level (top) to disease categories (down). It 
uses incidence and prevalence data of certain diseases, and it estimates the total financial 
burden related to one specific disease or group of diseases. This approach is valuable in 
principle, but it is highly dependent on the information available in national statistics and 
accounting practices adopted by a given country. Despite its simplicity, limited comparable 
evidence is available on the financial burden of CVD across countries.  
 
In recent years, few international organisations have made a considerable effort to refine 
their data collection methodologies and provide estimates of CVD related health 
expenditures across countries.  Eurostat and OECD have jointly collaborated on projects to 
develop a set of guidelines for the distribution of spending by disease, age and gender. To 
increase the comparability of the estimates of expenditures for health conditions across 
countries, the OECD adopted the System of Health Accounts (SHA). This approach was 
developed in 2000 to provide an updated and systematic description of the financial flows 
related to the consumption of health care goods and services at an international level.  
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In 2008, the OECD completed a project entitled Estimating Expenditure by Disease, Age and 
Gender under the SHA Framework.18 In the first phase, a set of guidelines was developed 
covering the main concepts and definitions and a methodology to allocate health 
expenditures (as defined under SHA) according to disease, age and gender. In a nutshell, 
OECD adopted a top-down method to allocate total current healthcare expenditure into 
different disease areas using the following approach. First, total health expenditure is 
portioned into so-called homogeneous cost-units (hospital inpatient, outpatient, primary, 
etc.). Then, cost-unit specific utilisation keys are constructed based on health care utilisation 
data retrieved from the national  
data sources. Subsequently, health expenditure for a cost unit (from step 2) is multiplied 
with utilisation key (from step 3) to establish a partial financial burden of disease for this 
unit. Aggregate partial tables for each unit to develop the total economic cost of the 
disease. 
 
The second phase of the project consisted of a pilot study to test the feasibility of 
implementing these draft guidelines under differing health care system characteristics in six 
countries (Australia, Germany, Hungary, Korea, Slovenia and Sweden) with varying degrees 
of experience in undertaking such studies. In 2016, OECD released data on health spending 
by disease, age and gender for the first time for these six countries. 
 
These OECD data show that CVD account for more than 10% of current health expenditure as 
well as the largest share of inpatient and pharmaceutical spending. In Hungary, the 
cardiovascular expenditure reached almost 16% of total CHE in 2006, while the lowest value 
occurred in the Netherlands (11% in 2011). Unfortunately, it is currently only feasible to 
derive these estimates for a limited number of countries and observation years. Hopefully, 
the OECD project will increase the number of countries for which similar data will become 
available.   
 
Contemporary with OECD, Eurostat made significant efforts in their data collection activities 
to estimate healthcare expenditures associated with specific diseases in European countries.  
In November 2013, Eurostat commissioned a 30-month research programme Health 
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Expenditures by Diseases and Conditions (HEDIC) from a consortium consisting of 
representatives from European Member States. The primary aim of the research was to 
develop further the methodology under the SHA, and hence to provide more detailed 
information on health care expenditure concerning its uses, as a contribution to the public 
health statistics available for monitoring EU health. HEDIC built on the experiences of OECD 
project and expanded the number of countries included in the analysis to eleven (Bulgaria, 
Czech Republic, Germany, Greece, Latvia. Lithuania, Hungary, Netherlands, Slovenia, Finland 
and Sweden). 
 
In 2016, HEDIC published its first report with the estimates of healthcare expenditure across 
different disease chapters defined by the International Classification of Diseases (ICD) of the 
World Health Organisation (WHO).19 CVD, represented by the ICD-10 codes I00-I99, covered 
a range of illnesses related to the circulatory system. These diseases include heart attack and 
cerebrovascular diseases such as stroke. HEDIC data confirm the previous OECD findings: CVD 
health expenditures was the most important category in all 11 countries, including about one-
sixth of current health expenditures in 2013. More specifically, the % of CVD related 
healthcare expenditure of the total healthcare expenditure ranged from 10.4% in Sweden to 
more than 22% in Bulgaria and almost 24% in Lithuania. Interestingly, the Eurostat report 
concludes that health expenditure for CVD is stagnating in recent years (variations ranged, 
and the authors suppose that this is because treatment is getting cheaper. As a consequence, 
the share of health expenditure devoted to CVD is diminishing compared to previous years 
but remains a very significant component of the overall healthcare expenditure. 
 
Both OECD and HEDIC study demonstrated the general feasibility of estimating expenditures 
by disease, in a wide range of national settings and data contexts.  
However, as of today, there are no systematic data on CVD health expenditure across the 
majority of 56 countries included in the Atlas project.  This evidence gap raises a significant 
challenge that should be addressed. 
 
It is important to emphasise that the efforts made by OECD and Eurostat only provide 
estimates of the financial burden of cardiovascular diseases. It uses expenditure data derived 
from accounting records. Although potentially very useful for informing policies, there are 
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significant limitations to this approach. First, as highlighted in the examples above, financial 
analysis is limited to healthcare expenditure data, thus reflecting only the portion of the costs 
associated with CVD.  From a strictly methodological point of view, financial costs are 
inherently different from economic costs, which reflect the total burden of a specific disease 
(or group of diseases) from a societal perspective.  
 
3.4. Economic burden of cardiovascular diseases 
Cost-of-illness (COI) analysis represents the earliest form of economic evaluation in the health 
care sector.17 20 21 The principal aim of COI is to evaluate the economic burden diseases impose 
on society as a whole. COI adopt a societal perspective which implies consideration of not 
only direct healthcare costs but also those falling outside the healthcare sector. These indirect 
costs include opportunity costs associated with unpaid care (i.e. informal care) and 
productivity losses associated with premature death or morbidity. Cost of illness studies have 
hugely advanced in recent decades in the methods used. They provide several stakeholders 
(e.g. policymakers, payers, industry) with relevant insights not only related to the economic 
burden of diseases (i.e. to unveil neglected areas). Importantly, they show who bears the 
costs and what are the possible areas to increase efficiencies.22 
 
Given the enormous 
 potential of COI, it is somewhat surprising that there are very few studies that aimed to 
estimate the economic burden of CVD at international level systematically. In contrast to the 
lack of evidence at a global scale, there have been numerous initiatives at the national level 
that estimated economic costs of one or more CVD (see for example:23 24 25 26 27 28 29). Also, 
few systematic reviews have been published recently.30 31 32 
 
A comprehensive review of national COI studies in 56 ESC countries was beyond the scope of 
this manuscript. Providing meaningful comparison of country-level estimates is very 




Instead, to provide some insights into the economic burden of CVD in ESC countries, we 
report on two international initiatives. To the best of our knowledge, these two are the only 
international COI studies of CVD conducted so far.  
 
The first study was published more than a decade ago by Leal et al., 2006 and represented a 
full mark in international comparative assessments in the economic burden of cardiovascular 
diseases.33  The study focused on the countries in the enlarged European Union and adopted 
a comprehensive methodology to estimate the societal costs of CVD. We estimated 
healthcare costs from health expenditure on primary, outpatient, emergency, and inpatient 
care, as well as medications. We included costs of informal care and lost earnings 
(productivity losses) due to morbidity and premature death.   
 
The study was the first to assess the economic burden of CVD across the EU and provided 
valuable insights into the overwhelming burden of CVD in Europe. CVD was estimated to cost 
the EU €169 billion annually, with healthcare accounting for 62% of costs. Productivity losses 
and informal care represented 21% and 17% of costs, respectively. CHD represented 27% and 
cerebrovascular diseases 20% of overall CVD costs. 33 
 
A few years later, the European Heart Network conducted a similar exercise to provide more 
updated estimates of the economic burden of CVD in the EU. The EHN estimated the CVD cost 
to the healthcare systems of the EU at just over €106 billion in 2009.34 As for cost per capita, 
this meant €212 per annum, around 9% of the total healthcare expenditure across the EU. 
The EHN recently published the latest estimates of the economic burden of CVD in EU 
countries. The EHN considered healthcare costs, informal care and productivity losses both 
due to premature mortality and morbidity. More specifically, healthcare costs included: 
primary care, outpatient care, A&E, inpatient care and medications. In addition to the total 
costs of CVD, they also analysed specific costs of IHD and cerebrovascular diseases (i.e. 
stroke).35 
 
Overall, CVD is estimated to cost the EU economy €210 billion a year (2015). Of the total cost 
of CVD in the EU, around 53% (€111 billion) is due to health care costs, 26% (€54 billion) to 
productivity losses and 21% (€45 billion) to the informal care of people with CVD (Figure 3.3). 
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Within health care costs, the cost of inpatient hospital care for CVD patients accounted for 
about 51%, and that of drugs for about 25%. Total costs of IHD amounted to approximately 
€59 billion, with informal care costs representing the highest percentage of the total expenses 
(€20 billion, 35%). Cerebrovascular disease accounted for nearly €45 billion, with direct 
healthcare costs consuming the largest share (€20 billion, 44%).19  
 
The EHN study highlights the great variation across 28 EU countries of CVD economic burden, 
both in terms of absolute values (cost per capita) as well as % of total healthcare expenditure 
dedicated to CVD.  CVD direct healthcare cost per capita ranged from €48 in Bulgaria to €365 
in Finland. In 6 EU countries (Bulgaria, Croatia, Romania, Latvia, Lithuania and Cyprus) direct 
healthcare cost per capita was below €100, while Hungary had the highest % of total 
healthcare expenditure consumed by CVD (19% of the total healthcare expenditure). 35 
 
Also, the distribution of costs across different cost categories significantly varied across EU 
countries, suggesting very diverse approaches to the management of CVD (Figure 3.4). For 
example, % of total CVD costs associated with hospitalisations (inpatient care) was 
particularly low (less than 10%) in four countries (Cyprus, Latvia, Portugal and Croatia) while 
it represented a significant cost category (more than 40%) in France and Finland. Outpatient 
care in Cyprus and Slovakia represented approximately 15% of total costs dedicated to CVD, 
more than double of the average for the whole EU (6.8%). Pharmaceutical expenditure was 
particularly important in Greece (28% of the total CVD costs), while it reached only 7% in 
Northern European countries such as Sweden and Finland.  
Regarding non-healthcare costs, informal care revealed significant disparities across EU 
countries. The % of total expenses dedicated to informal care ranged from a minimum of 7% 




The global burden of CVD disease is not only a health issue but an enormous economic 
challenge to healthcare systems across the globe and is expected to grow the future years[20] 
exponentially.36 Policymakers must have access to reliable and valid evidence.    
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There is an urgent need to systematically collect standardised evidence on the financial and 
economic burden of CVD across all ESC member countries. This information has the potential 
to provide a platform for the analysis of resource allocation across ESC countries and provide 
invaluable evidence to policymakers for designing effective health policies aimed to reduce 
the burden of CVD across the globe. 
 
OECD, Eurostat, EHN have made essential contributions but – at present - these have not 
turned it systematic and stable data collection efforts in the field of cardiovascular care. 
 
The ESC Atlas initiative has the considerable potential to become a platform for collecting 
relevant data on the burden of CVD, in addition to all other relevant cardiovascular statistics 
presented in this manuscript. It will be necessary to assess the feasibility and desirability of 
working towards the general aim of routine collection from all ESC countries on the financial 
and economic costs of CVD.    
 
3.6. Comment 
Cardiovascular disease is a significant driver of the global burden of disease. This global 
burden of disease involves all aspects of the healthcare system, including public health 
programmes and preventive services, primary care, emergency and acute care, as well as 
rehabilitative and long-term care. Furthermore, CVD pose a significant burden on patients 
and their families.  CVD is no longer just a health issue, but a significant financial and economic 
hardship for individuals, health systems and societies across the globe. World Heart 
Federation recently estimated that by 2030, the total global cost of CVD is set to rise from 
approximately US$863 billion in 2010 to a staggering US$1,044 billion. 
 
This aim of this chapter was to provide an overview of available empirical evidence on the 
financial and economic burden of CVD across 56 countries participating in ESC Atlas project. 
  
At present, there is a significant and undeniable lack of international, systematic and 
comparative evidence on the economic and financial burden of CVD in ESC countries. 
International institutions and academic scholars have made some critical contributions to the 
field, but their efforts are limited impacting on the reliability of estimates obtained. 
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Efforts made by OECD and Eurostat demonstrated the general feasibility of estimating health 
expenditures by disease. The efforts have also shown that the SHA framework has the 
potential to provide a large amount of information for the analysis of health resource 
allocation in the European health system. However, as of today, the data for only a few 
countries and years are available given the constraints in standardised data collection across 
countries. Due to the differing structure of healthcare systems and national registrations in 
some countries, the creation of cost-units along a functional dimension pivotal for SHA may 
not always be currently possible. The success of any future data collection and the perceived 
value of the international comparisons depends on the application of the final guidelines and 
the transparency of the methodologies used and the broader issues concerned with the 
revision of the SHA framework.  
 
Studies on economic costs of CVD have limited their focus to European countries. 17 18 19 
Findings obtained were constrained mainly by the availability of data in different countries.  
The authors of studies had to make numerous suppositions in estimating the total costs of 
CVD for all countries in the sample. For example, in the most recent study published by the 
EHN necessary data for the majority of healthcare cost categories considered only for a small 
subset of countries. Only costs related to hospital inpatient care were directly available from 
all countries, as it uses national sources of hospital discharges. For all other healthcare cost 
categories (i.e. primary care, outpatient, emergency and medications), authors were obliged 
to make a series of essential assumptions. For example, in a vast majority of countries (17 out 
of 28), data on CVD related primary care visits was not available. The number of CVD related 
primary care visits was estimated by multiplying the total number of primary care visits with 
the proportion of hospital discharges due to CVD. This calculation relies on the implicit 
assumption that a percentage of patients leaving inpatient care due to CVD would be followed 
up in GP consultations. A similar approach was used to estimate the number of outpatient 
visits in 18 EU countries. Estimates were inflated using the proportion of private expenditure 
on healthcare if only public resource use was recorded. Also, for non-healthcare costs 
(informal care and productivity losses), authors had to rely on direct estimates for only a small 
sample of countries. For the countries with missing data, authors made assumptions about 
"similarity" of nations to transfer the results across different jurisdictions.  
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4. Risk factors and health behaviour 
 
The identification of major risk factors that predispose to the development of non-fatal and 
fatal cardiovascular disease (CVD) was a key contribution of the Framingham Heart Study.37 
The Framingham findings have been extensively validated and their global importance was 
confirmed in INTERHEART, a case-control study conducted in 52 countries, which showed that 
only nine potentially reversible risk factors and health behaviours (alcohol, hypertension, 
dyslipidaemia, diabetes, diet, obesity psychosocial factors, sedentary lifestyle and smoking) 
account for >90% of the population attributable risk of acute myocardial infarction (AMI) in 
all regions of the world38.  While these risk factors make just a modest contribution to 
outcome, their control or elimination are calculated to make a substantial reduction in 
incident CVD at population level.39   
This is the perspective underpinning the Global Action Plan, launched by the WHO for 2013-
2020.40 The plan sets targets to be achieved by 2025 for intensive control of behavorial 
(harmful use of alcohol, physical inactivity, tobacco use) and biological (raised blood pressure 
and lipids, diabetes and obesity) risk factors and for a significant reduction of cardiovascular 
mortality and morbidity worldwide. 
In this section, the prevalence and time course of risk factors and health behaviours for ESC 
member countries are presented.  
 
4.1 Risk factors 
4.1.1 Blood pressure.  
Data source:  
Completeness:  
Year of data:  
 
There is a continuous linear relationship between blood pressure levels and the risk of stroke 
or myocardial infarction.41 International surveys show that the rate of elevated systolic blood 
pressure (≥110-115 and ≥140 mm Hg) has increased substantially between 1990 and 2015 
with knock-on effects on disability-adjusted life years and deaths attributable to 
hypertension.42 The INTERHEART study estimated that 22% of myocardial infarctions in 
Europe are related to hypertension, which almost doubles the risk compared with people 
with no history of hypertension. 38 Treatment to lower blood pressure provides significant 
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protection against cardiovascular events, with incremental benefits of more intensive 
treatment in patients at higher risk (concomitant vascular disease, renal disease or 
diabetes).43 
 
 National statistics. In 2015, the median age-standardized prevalence of raised blood 
pressure (defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 
mmHg) across ESC member countries was 24.8% (IQR 19.8% to 28.5%), ranging from 
15.2% in the UK to 32.4% in Croatia (FIGURE 4.1). Blood pressure levels also varied across 
countries, with systolic values in women of 115 mmHg in Switzerland compared with 130 
mmHg in Republic of Moldova and in men of 120 mmHg in Turkey compared with 137 
mmHg in Croatia, Lithuania and Slovenia. 
 Stratification by sex. The prevalence of hypertension in all the ESC member countries for 
which data were available was lower in women than in men (FIGURE 4.2), with median 
rates of 22.3% (IQR 15.5% to 23.9%) and 27.0% (IQR 24.2% to 33.6%), respectively. This 
was reflected in median systolic blood pressure levels of 123.0 (IQR 118.9 to 126.1) mmHg 
in women and 130.0 (IQR 127.4 to 134.3) mmHg in men averaged across member 
countries.  
 Stratification by national income status: The median age-standardized prevalence of 
raised blood pressure in women and men was 15.7% (IQR 14.5% to 21.1%) and 25.2% (IQR 
23.6% to 34.3%) in high-income ESC member countries and 23.8% (IQR 22.5% to 25.1%) 
and 29.7% (IQR 25.4% to 33.2%) in middle-income countries (FIGURE 4.2). Systolic blood 
pressure levels also varied by national income status, with median levels for women and 
men of 119.5 (IQR 117.3 to 121.4) mmHg and 128.1 (IQR 126.9 to 132.2) mmHg in high-
income countries and 126.0 (IQR 124.8 to 127.5) mmHg and 133.1 (IQR 129.6 to 134.9) 
mmHg in middle-income countries (Figure 4.3). 
 Time series data: The median age-standardised prevalence of raised blood pressure 
across all ESC member countries trended downwards between 1980 and 2015 from 35.3% 
(IQR 31.7% to 38.4%) to 24.8% (IQR 19.8% to 28.5%) (Figure 4.4). The declines were 
greater in high income countries (37.1% (IQR 34.2% to 39.9%) to 20.3% (IQR 19.3% to 
27.8%)) compared with middle income countries (33.1% (IQR 31.0% to 36.1%) to 26.9% 
(IQR24.9% to 28.6%)). 
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 WHO non-communicable disease (NCD) targets. The WHO has called for a 25% reduction 
(with reference to 2010) in the prevalence of raised blood pressure, to be achieved by 
2025. During this period the median prevalence of raised blood pressure across ESC 
member countries has declined by 8.4% (IQR 12.0% to 5.6%) with declines of 10.7% (IQR 
12.9% to 7.5%) and 6.0% (IQR 8.3% to 3.0%) in high income and middle income countries. 
Encouraging though these trends are, it seems unlikely that the WHO blood pressure 
target for 2025 will be met. 
 
4.1.2 Cholesterol.  
Data source: 
Completeness:  
Year of data: 
  
Epidemiological and Mendelian randomisation studies have identified cholesterol, 
particularly LDL cholesterol, as a major determinant of cardiovascular disease, with risk 
increasingly linearly as blood concentrations increase.44,45 Cholesterol is a major target of risk 
reduction programmes in which statin therapy in men and women with no history of vascular 
disease can produce a 15% reduction in risk of vascular death for each 1-mmol/L reduction of 
LDL cholesterol.46 47 48 The prevalence of raised total cholesterol associates with national 
income status and exceeds 50% in high-income countries including Europe.49 This compares 
with prevalence rates of less than 30% in Africa and South East Asia.  
 National statistics stratified by gender: Data for 2008 showed that the median blood 
cholesterol concentration averaged across all ESC member countries was 5.1 mmol/L (IQR 
xx to yy mmol/L) in both women and men, ranging from 4.5 and 4.4 mmol/L in women and 
men from Kyrgyzstan to 5.6 mmol/L in women and men from Iceland. The median age-
standardized prevalence of hypercholesterolaemia (>6.2 mmol/ L) averaged across 
member countries was 16.5% (IQR: xx to yy%) and 16.3% (IQR xx to yy%) in women and 
men, ranging from <10% in Azerbaijan, Bosnia and Herzegovina, Republic of Georgia, 
Kyrgyzstan, Republic of Moldova, and Turkey to >20% in Belgium, Finland, France, 
Germany, Ireland, Norway, and UK (FIGURE 4.5). 
 Stratification by national income status: Age-standardized median blood cholesterol 
concentrations in women and men were 5.2 (IQR xx to yy) mmol/L and 5.3 (xx to yy) 
mmol/L in high-income countries and 4.9 (IQR xx to yy) mmol/L and 4.8 (IQR xx to yy) 
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mmol/L in middle-income countries. This difference between high- and middle-income 
countries was reflected in median age-standardized prevalence rates for 
hypercholesterolaemia (≥6.2 mmol/L) that were 18.7% (IQR xx to yy%) and 18.8% (IQR xx 
to yy%) in women and men from high-income countries and 11.9% (IQR xx to yy%) and 
12.6% (IQR xx to yy%) in women and men from middle-income  countries (FIGURE 4.6). 
Between 1980 and 2009, blood cholesterol concentration across high-income countries, 
changed from a median of 5.9 (IQR xx to yy) mmol/L to 5.2 (IQR xx to yy) mmol/L in women 
and from 5.9 (IQR xx to yy) mmol/L to 5.3 (IQR xx to yy) mmol/L in men. Quantitatively 
similar changes were recorded in women (5.3 (IQR xx to yy) mmol/L to 4.9 (IQR xx to yy) 
mmol/L) and men (5.3 (IQR xx to yy) mmol/L to 4.8 (IQR xx to yy) mmol/L) in middle-income 
countries. 
 Time series data: Median blood cholesterol concentrations across ESC member countries 
declined from 5.6 (IQR xx to yy) mmol/L  to 5.1 (IQR xx to yy) mmol/L in women and from 
5.5 (IQR xx to yy) mmol/L  to 5.1 (IQR xx to yy) mmol/L in men between 1980 and 2009 
(FIGURE 4.7a, 4.7b). 
   
4.1.3 Diabetes.  
Data source: 
Completeness: 
Year of data: 
 
The WHO reports 422 million people currently living with diabetes (mainly type 2), of whom 
over 60 million live in Europe. The prevalence of diabetes has risen dramatically in the last 30 
years, both in men and women, with no substantial worldwide difference between high-, 
middle- or low-income countries (WHO, accessed 2019).50 This is largely attributed to 
overweight and obesity, which in turn are driven by excess dietary calories and physical 
inactivity. Diabetes is one of the “noncommunicable diseases” (NCDs) responsible for 63% of 
deaths worldwide, including 14 million premature deaths before the age of 70. More than 
90% of these premature deaths occur in low- and middle-income countries, and could largely 
have been prevented.50 
 
 National statistics: The median prevalence of diabetes by 2017 estimates in women and 
men aged 20-79 years averaged 6.8% (IQR 5.3% to 8.4%) across ESC member countries, 
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ranging from ≤ 4% in Estonia, Ireland, Lithuania to ≥ 10 % in Albania, Bosnia and 
Herzegovina, Egypt, Lebanon, Lybia, Macedonia, Montenegro, Serbia and Turkey (Figure 
4.8).  
 Stratification by National Income Status The median prevalence of diabetes in people 
aged 20-79 was greater in middle-income countries (7.7% (IQR 7.1% to 10.1%)) compared 
with high-income countries (5.6% (IQR 4.8% to 7.0%)), with prevalence greater than 12% 
in Egypt, Lebanon and Turkey  (Fig 4.9).  
 Time series data: The proportion of people older than 15 with diabetes across those ESC 
member countries with data available increased from a median of 1.09% (IQR 0.79% to 
1.47%) in 1990 to 3.93% (IQR 2.73% to 5.55%) in 2015  (Fig 4.10).  
 WHO non-communicable disease (NCD) targets. The WHO has called for a halt (with 
reference to 2010) to the rise in diabetes, to be achieved by 2025. However, analysis of 
paired 2010 and 2015 national data available for 26 countries, showed a sharp 31.3% 
increase in the median prevalence of diabetes from 3.2% (IQR 2.0% to 4.8%) to 4.2% (IQR 
2.8% to 5.7%) during that period. This was particularly marked in middle income countries 
where the prevalence of diabetes increased by 37.0% compared with 12.4% in high income 
countries.  These statistics suggest it is very unlikely the WHO diabetes target will be met, 
particularly in middle income countries.  
 
4.1.4 Obesity  
Data sources: 
Completeness: 
Year of data:  
 
The prevalence of overweight and obesity, defined by a body mass index (BMI) of ≥25 kg/m2 
and ≥30 kg/m2, respectively, is increasing in both developed and developing countries. More 
people are now obese than are underweight both globally and in most regions of the world.51 
The obesity epidemic has largely been driven by global trade liberalization, economic growth 
and rapid urbanization affecting lifestyle and food intake, with a trend towards a larger 
consumption of animal fat and added sugar.52 In 2016 the Global BMI Mortality Collaboration 
meta-analysis concluded that the consequences of an increased body mass – index for all-
cause mortality were severe and consistent across Europe, North America, Asia, Australia and 
New Zealand. 53 
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 National statistics: Median age-standardized body mass index (BMI) averaged across the 
ESC member countries in 2016 was 26.6 (IQR 26.1 to 27.1) kg/m2 and was similar for 
women (26.2 (IQR 25.5 to 26.9) kg/m2) and men (27.0 (IQR 26.4 to 27.3) kg/m2) (Fig 4.11). 
BMIs among women ranged from 23.7 kg/m2 in Switzerland to 31.4 kg/m2 in Egypt and 
among men from 25.7 kg/m2 in Algeria to 28.2 kg/m2 in Hungary. Data for 2016 showed 
that, across ESC member countries, approximately one in five adult women and men were 
obese (≥30 kg/m2), as reflected by prevalence rates of 22.8% (IQR 21.0% to 26.1%) and 
22.3% (IQR 20.3% to 24.2%), respectively (Fig 4.12). Female obesity was particularly 
common in Egypt and Libya, where it affected more than one in three women, while male 
obesity was common in Malta, Hungary, Czech Republic, UK and Lebanon, where it 
affected more than one in four men.  
 Stratification by national income status: Median BMI in women and men averaged across 
ESC member countries was 25.8 (IQR 25.2 to 26.3) kg/m2 and 27.0 (IQR 26.6 to 27.5) kg/m2 
in high-income countries and 26.7 (IQR 26.3 to 27.5) kg/m2 and 26.8 (26.1 to 27.1) kg/m2 
in middle-income countries. The prevalence of obesity in women and men was 21.4% (IQR 
20.1% to 25.0%) and 23.7% (IQR 21.9% to 24.4%) in high-income countries and 24.1% (IQR 
22.0% to 34.4%) and 21.0% (IQR 18.7% to 22.9%) in middle-income countries (Fig 4.13).   
 Temporal changes The median age standardized prevalence of obesity across ESC member 
countries increased sharply between 1980 and 2016 from 9.6% (IQR 8.2% to 11.9%) to 
22.6% (IQR 20.9% to 25.8%)(Fig 4.14). Increases in population obesity were similar in high-
income and middle-income countries 
 WHO non-communicable disease (NCD) targets. The WHO has called for a halt (with 
reference to 2010) to the rise in obesity, to be achieved by 2025. However, analysis of 
paired 2010 and 2015 national data, showed an increase in the prevalence of obesity  in 
women from 20.4% (IQR 18.9% to 24.8%) to 22.8% (IQR 21.0% to 26.1%) and men from 
19.2% (IQR 17.1% to 21.1%) to 22.3% (IQR 20.3% to 24.2%).  These statistics suggest it is 




Year of data: 
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Tobacco consumption has been described as the “single largest avoidable health risk in the 
European Union” by the European Commission’s Directorate-General for Health and Food 
safety.54  Tobacco use is linked to many forms of cancer and cardiovascular diseases and is 
the major determinant of death for nearly 6 million people a year. This is why policy measures 
related to tobacco use and tobacco derivative commercialization have been promoted by the 
EU in the last 15 years. During this period there has been continuous decline in the prevalence 
of smoking across Europe.55 
 National statistics In men and women aged ≥15 years, the median prevalence of regular 
daily smoking by 2014 estimates was 21% (IQR 18.2% to 25.7%), based on data from 29 
ESC member countries. Prevalence ranged from 11.9% in Sweden to 36.1% in Latvia (FIG 
4.15). 
 Stratification by gender: Across ESC member countries, men were heavier smokers than 
women with median prevalence rates by 2014 estimates of 26.5% (IQR 21.7% to 33.5%) 
compared with 15.0% (IQR 12.1% to 18.5%), respectively (FIG 4.15). Prevalence in men 
ranged from <15% in Sweden, Norway and Iceland to ≥40% in Latvia, Albania, Armenia, 
Belarus and Ukraine. For women, prevalence ranged from <10% in Armenia, Albania, 
Azerbaijan, Lithuania and Belarus to >20% in Hungary, Greece, France, Croatia and Austria. 
It is noteworthy that Latvia, Albania and Belarus were  at the top of the smoking leagues 
for men and for women, emphasising the importance of cultural factors in determining 
smoking behaviour.  
 Stratification by national income status Comparison of smoking prevalence in high- and 
middle-income ESC member countries showed divergent differences in women and men 
aged ≥15 years (Fig 4.16). Among women, smoking prevalence by 2014 estimates was 
higher in high-income countries (16.7% (IQR 13.9% to 19.7%)) compared with middle-
income countries (8.7% (IQR 3.0% to 10.8%)) but for men smoking prevalence was lower 
in high income countries (26.0% (IQR 20.9% to 31.7%)) compared with middle-income 
countries (43.8% (IQR 37.4% to 48.0%)).   
 Temporal changes Between 1995 and 2014 the national prevalence of smoking across ESC 
member countries in people aged ≥15 years declined from 28.0% (IQR 25.6% to 33.6%) to 
21.0% (IQR 18.2% to 25.7%) (Fig 4.17).  Declines were similar in women and men and in 
high-income and middle-income countries 
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 WHO non-communicable disease (NCD) targets The WHO has called for a 30% relative 
reduction in prevalence of tobacco use in persons aged 15+ years, to be achieved by 2025 
(reference to 2010). Paired prevalence data for daily smoking between 2010 and 2014-16 
were available for only 15 high-income and 5 middle-income countries. During that period 
the median prevalence of daily smoking reduced by 10.1% in women from 15.8% (IQR 
13.5% to 19.3%) to 14.2% (10.7% to 16.8%) and by 14.8% in men from 28.3% (IQR 20.8% 
to 36.2%) to 24.1% (IQR (18.7% to 34.3%). Based on these data the WHO target appears 
feasible for ESC member countries.  
 
4.2.2 Alcohol.  
Data sources: 
Completeness: 
Year of data: 
 
Alcohol consumption is defined as the recorded amount (in litres) of pure alcohol consumed 
per adult (15+years) over a calendar year and is a European Core Health Indicator 
(ac.europa.eu, 2019).54 The indicator only takes into account the consumption that is 
recorded from production, import, export, and sales data, often via taxation. Recommended 
upper limits for alcohol consumption vary by country (Fig 4.18).   
Excessive alcohol consumption remains a leading cause of premature death in the USA where 
it is responsible for 1 in 10 deaths among working-age adults. 56 In the European Union, 
harmful alcohol use is the third biggest cause of premature death after tobacco and 
hypertension while alcohol dependence is estimated to be responsible for more than 60% of 
all alcohol-attributable mortality.57  
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Fig 4.18. Alcohol consumption: recommended upper limits in men and women (ml/wee  
 National statistics: Data for 2016 show that 66.6% (IQR 41.9% to 73.3%) of people aged 
≥15 years living in ESC member countries had consumed alcohol in the previous 12 months, 
with a median consumption of 10.2 (IQR 7.5 to 11.7) L/capita/year (Fig 4.19).  There were, 
large differences between countries, with consumption ranging from <4 L/capita/year in 
Israel, Algeria, Azerbaijan, Egypt, Lebanon, Lybia, Morocco, Syria, Tunisia and Turkey, to > 
12  L/capita/year in Belgium, France, Germany, Latvia, Portugal, Slovenia, Bulgaria, 
Moldova and Romania. (Table NN, Figure NN). Cultural and religious factors  likely 
contribute to the very low alcohol consumption in many Middle East and North African 
countries. 
 Stratification by sex: Across all ESC member countries, data for 2016 show that fewer 
women (55.1% (IQR 28.9% to 62.9%)) than men (79.4% (IQR 56.1% to 84.2%)) had 
consumed alcohol in the previous 12 months. Median consumption among women (4.1 
(IQR 2.5 to 5.1) L/capita/year) was accordingly lower compared with men (16.8 (IQR 11.8 
to 19.4) L/capita/year) and this was a consistent finding across nearly all ESC member 
countries (FIG 4.20). Age standardised median prevalence rates for heavy episodic drinking 
(defined as consumption of at least 60 g of pure alcohol on at least one occasion in the 
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past 30 days) were likewise lower in women (15.0% (IQR 7.8% to 20.1%)) compared with 
men (47.4% (IQR 32.0% to 55.9%)) (FIG 4.21). Rates ≥ 60% were recorded for men in Czech 
Republic, Estonia, Latvia, Luxembourg and Slovenia. Rates tended to be high among 
women in these same countries and exceeded 30% for women in Latvia, Lithuania and 
Luxembourg.  
 Stratification by national income status: In 2016, the median prevalence of alcohol 
consumption in the previous 12 months was 72.7% (IQR 68.2% to 76.2%) in high-income 
countries, which was almost double the prevalence in middle-income countries (37.5% 
(IQR 5.9% to 58.6%). Accordingly, median alcohol consumption was higher in high-income 
(11.5 (9.4 to 12.5) L/capita/year) compared with middle-income countries (7.0 (1.4 to 10.1) 
L/capita/year) for both women and men (Fig 4.20).  Nevertheless, there was considerable 
variation with consumption in high income countries ranging from 3.8 L/capita/year in 
Israel to 15.0 L/capita/year in Lithuania and in middle-income countries from 0 
L/capita/year in Libya to 15.2 L/capita/year in Moldova. Heavy episodic drinking showed a 
similar pattern with prevalence rates higher in high income (35.7% (31.4% to 39.9%)) 
compared with middle-income (19.2% (1.3% to 27.2%)) countries for both women and 
men (Fig 4.21), although there was considerable variation by country. 
 WHO non-communicable disease (NCD) targets. The WHO has called for a 10% relative 
reduction in the harmful use of alcohol, to be achieved by 2025 (reference to 2010). Paired 
2010/2016 data show that median alcohol consumption across ESC member countries has 
declined by 8.9% from 11.2 (IQR 7.1 to 12.3) L/capita/year to 10.2 (IQR 7.5 to 11.7) 
L/capita/year. The decline was limited almost exclusively to middle-income countries 
where consumption declined by 8.6% compared with an increase of 0.4% in high-income 
countries. These data suggest the WHO alcohol target is feasible, particularly for middle-
income countries.  
 
4.2.3 Vegetable and fruit consumption.  
Data sources: 
Completeness: 
Year of data: 
 
Low fruit and vegetable intake are recognized risk factors for noncommunicable diseases, 
such as cancer and coronary heart.58 In a systematic review and dose-response meta-analysis 
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of 95 prospective studies, progressive reductions in the risk of cardiovascular disease and all-
cause mortality were observed up to an intake of 800 g/day of fruit and vegetables combined, 
whereas for total cancer no further reductions in risk were observed above 600 g/day.59  Like 
all studies examining relations between  nutrition and disease cautious interpretation is 
necessary, partly because of confounding by healthy lifestyle that makes nutritional 
contributions to risk reduction hard to ascertain and partly because of variable lack of 
precision in the dietary measurement. Similar caution needs exercising in interpreting the 
dietary data recorded in the Atlas.  
   
 National statistics The most recent available estimates for vegetable and fruit 
consumption were obtained in 2014 for people aged ≥15 and were limited to 22 high-
income countries and one middle-income country (Turkey). Across these 23 ESC member 
countries 52.2% (IQR 44.1% to 60.5%) of people consumed at least one portion of 
vegetables per day and 55.0% (IQR 47.4% to 60.9%) consumed at least one portion of fruit 
per day.  Vegetable consumption was greatest in Israel where 81.0% of the population 
consumed at least one portion per day compared with <35% of the populations of 
Netherlands and Germany. Fruit consumption was greatest in Italy and Israel where >70% 
of the populations consumed at least one portion per day compared with only 20.2% in 
Latvia.  
 Stratification by sex Across ESC member countries, a greater proportion of women (61.2% 
(IQR 55.8% to 68.3%)) consumed at least one portion of fruit per day  compared with men 
(45.9% (39.6% to 52.7%)). The proportion of women consuming at least one portion of 
vegetables per day (59.5% (IQR 50.1% to 64.5%)) was also greater compared with men 
(43.4% (IQR 36.1% to 55.3%)).  
 Temporal changes Paired 2010/2014 data were available for just seven high-income 
countries plus Turkey. During this period Latvia and Iceland showed a substantial increase 







4.2.4 Physical Activity.  
Data sources: 
Completeness: 
Year of data: 
 
Physical inactivity is defined as the proportion of the population attaining less than 150 min 
of moderate-intensity physical activity per week or less than 75 min of vigorous-intensity 
physical activity per week. Inactivity increases the risk of several noncommunicable diseases 
such as ischemic heart disease, type 2 diabetes, breast and colon cancers, and accounts for 
nearly 10% of all deaths worldwide.60 Promotion of leisure time exercise has been described 
as “today’s best buy in public health”.61  
 National statistics by sex. In 2016 the median age standardised prevalence of self-
reported “insufficient” physical activity was 31% (IQR 26.3% to 35.8%) among adults aged 
≥18 across ESC member countries (Fig 4.22). The prevalence tended to be higher in 
women (33.9% (IQR 28.9% to 40.1%)) than men (26.4% (IQR 22.9% to 31.5%) with >43% 
of women in Cyprus, Germany, Italy, Malta and Portugal reporting insufficient physical 
activity compared with ≥ 35% of men in the same countries.  
 Stratification by national income status Median prevalence rates of insufficiently active 
women and men were higher in high-income countries (34.3% (IQR 31.0 to 40.7%) and 
28.2% (IQR 25.4% to 31.9%)) compared with middle-income countries  (31.4% (IQR 19.5% 
to 38.8%) and 23.2% (IQR 18.0% to 29.1%)) (Fig 4.23).   
 
4.3 Summary  
 Age standardised data for 2015 showed that almost one in four people in ESC member 
countries had raised blood pressure. Systolic blood pressure was higher in men compared 
with women and in middle-income countries compared with high income countries. Across 
nearly all countries, the prevalence of raised blood pressure has been trending downwards 
the last 35 years but it is unlikely that the WHO NCD target for 2025 will be met 
 
 Age standardised data for 2009 showed that blood cholesterol concentrations were similar 
in women and men but tended to be higher in high income compared with middle income 
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countries. Blood concentrations across all ESC member countries have shown a small 
downward trend the last 30 years 
 
 Across all ESC member countries more than one in 20 adults had diabetes by 2017 
estimates. The prevalence of diabetes was lower in high-income compared with middle-
income countries where it often exceeded 10%. Across all ESC member countries 
prevalence has increased more than three-fold the last 25 years. 
 
 Age standardised data for 2016 showed that, across ESC member countries, approximately 
one in four adult women and men were obese. The prevalence was a little higher in high-
income compared with middle-income countries and across all countries has increased 
more than two-fold the last 36 years. The WHO NCD target for a halt to the rise in obesity 
by 2025 is unlikely to be met. 
 
 More than one in five adults across ESC member countries were smokers by 2014 
estimates. Smoking was more common among men than women, particularly in middle-
income countries rates where 43.8% of men smoked compared with 10.8% of women. 
Across all countries smoking has declined by 31% the last 14 years. The WHO NCD target 
for a 30% reduction in tobacco use by 2025 appears feasible 
 
 Alcohol consumption by 2016 estimates was more than three times higher in men 
compared with women across ESC member countries and almost twice as high in high-
income compared with middle-income countries. Consumption since 2010 appears to be 
declining, particularly in middle income countries where the WHO NCD target for a 10% 
relative reduction in the harmful use of alcohol by 2025 appears feasible. 
 
 Physical activity by self-reported data in 2016 was graded insufficient in one in three adults 
living in ESC member countries. Rates of inactivity were somewhat higher in women 




The ATLAS data repository of risk factors and health behaviours provides a broad overview of 
the challenges confronting ESC member countries in the development of policies to reduce 
the burden of CVD. These challenges are particularly relevant in middle-income countries 
where disease burden is high, no doubt reflecting increased rates of hypertension, diabetes 
and smoking compared with high-income countries that we describe elsewhere in this report. 
The relative paucity of contemporary treatment facilities in many of these middle income 
countries completes the paradox of inferior healthcare provision where need is greatest that 
is enshrined in the inverse care law.3 Yet while the expense of modern cardiovascular 
technology is hard to prioritise in many countries, steps to tackle key risk factors represent a 
more realistic strategy for reducing CVD burden in middle income countries as they are more 
dependent on organisational change than large financial investment. Risk factors and 
unhealthy behaviours are potentially reversible, and this provides huge opportunity to 
address the health inequalities across ESC member countries that are highlighted in this 
report.  It seems clear, however, that efforts to seize this opportunity are falling short and 
present evidence suggests that most of the WHO NCD targets for 2025 are unlikely to be met. 
Rates of obesity and diabetes in particular are increasing and the ESC’s ambitious mission “to 





5. Cardiovascular disease morbidity 
  
 
Measures of morbidity play an important role in describing the epidemiology of a disease, as 
they represent the number of people who are suffering from it, within a population.62 
 
Prevalence measures, describe the number of individuals who currently have a particular 
disease in a given population. In the case of acute cardiovascular events, such as myocardial 
infarction or stroke, they signify the number of people living in the population, who have ever 
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suffered such an event. Incidence defines the number of new cases in a population over a 
given time, providing a measure of disease occurrence.  
 
Even for conditions with a relatively high case fatality, such as stroke and acute myocardial 
infarction, morbidity is an important measure alongside mortality, as the disability caused by 
suffering such events can be high in those that survive and there is some burden in treating 
individuals irrespective of their level of recovery.  
 
Compared to collecting mortality data, however, which involves aggregating the number of 
registered deaths, collecting morbidity data is more challenging. Despite the proliferation of 
electronic record systems within health services in most countries, few utilise such systems 
to report accurate records of morbidity. We must, therefore, rely on other sources for 
morbidity statistics.  
 
Throughout this chapter we present data from the Global Burden of Disease Study, which 
models morbidity estimates for countries using data from health surveys, prospective 
cohorts, health system administrative data, and registries 63 64 . Such estimates are 
invaluable in allowing morbidity comparisons between countries and over time.  
 
It must be remembered, however, that the strength of the original data source is key to the 
accuracy of the final modelled estimate 65 66 and we would encourage countries to develop 
more comprehensive and systematic means of collecting morbidity data for all conditions, 
including CVD. 
 
5.1 Incidence of CVD 
Data:  
Data source:  
Completeness:  
Year of data: 
 
Disease incidence is the rate of occurrence of new cases in a given population. It conveys 
information about the risk of contracting the disease. 
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 National statistics: In 2017, there were 19.9 million new cases of CVD in the 54 ESC 
member countries with data available. National contributions were in part determined by 
population size, with Germany and Russia each contributing about 2.5 million new cases 
and Iceland and Malta  contributing <10,000. The median, age-standardised incidence of 
CVD was 1132.72 (IQR 1002.4 to 1289.3) per 100,000 inhabitants of each member country, 
ranging from <900 in Turkey, Armenia, Kyrgyzstan and Lebanon to >1400 in Austria, Czech 
Republic, Finland, Iceland, Slovenia, Luxembourg and Romania (FIGURE 5.1). 
 Stratification by sex: In 2017, women accounted for more new cases of CVD across ESC 
member countries compared with men (10.3 million vs. 9.6 million) but after age-
standardisation, median rates per 100,000 people were lower in  women than in men 
(1005.8 vs 1290.8) (Supplementary Figures S5.1a and b, S5.2a and b). 
 Stratification by national income status: In 2017, the median age-standardised incidence 
of CVD per 100,000 inhabitants was lower in middle-income countries compared with high-
income countries (1039.4 (IQR 929.6 to 1206.9) vs 1224.4 (IQR 1106.4 to 1355.7)) for both 
women and men (FIGURE 5.2). In middle income countries, rates peaked at >1,300 in 
Romania and Bulgaria but in high income countries rates were yet higher peaking at >1,400 
in Austria and Czech Republic.  
 Time series data: The median age-standardised incidence of CVD per 100,000 inhabitants 
changed from 1185.9 (IQR 1078.2 to 1339.9) in 1990 to 1132.72 (IQR 1002.4 to 1289.3) in 
2017. Declines in median incidence rates per 100,000 inhabitants registered in 43 
countries were generally small with 11 countries registering an increase. Moldova and 
Estonia registered the greatest declines (>13%) but in those countries registering an 
increase it never exceeded 7.0% (FIGURE 5.3). 
 
5.1.1 Incidence of IHD 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 National statistics: In 2017, IHD was the most common manifestation of incident CVD with 
3.6 million new cases in the 54 ESC member countries with data available. The median age-
standardised rate per 100,000 inhabitants of each member country was 176.3 (IQR 150.0 
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to 238.0) and in both women and men rates were lowest in Portugal, Cyprus, Malta, Spain 
and Luxembourg and highest in Egypt, Morocco and Belarus   (Supplementary Figures 
S5.3-S5.6). 
 Stratification by sex: Women accounted for fewer new cases of IHD compared with men 
(1.6 million vs. 2.0 million), and with age-standardisation, median rates per 100,000 
inhabitants of ESC member countries were substantially lower in women than men (132.0 
(IQR 98.2 to 174.6) vs 235.9 (IQR 208.8 to 310.0)) (FIGURE 5.4). 
 Stratification by national income status: The median age-standardised incidence of IHD 
per 100,000 inhabitants was higher in middle-income countries compared with high-
income countries (243.0 (IQR 175.7 to 282.3) vs 160.5 (IQR 140.0 to 193.5)) (FIGURE 5.4). 
In middle income countries, the incidence rate varied between 142.9 and 420.0 in Albania 
and Egypt while in high income countries it varied between 66.3 and 267.2 in Portugal and 
Lithuania. 
 Time series data: Between 1990 and 2017, the median age-standardised incidence of IHD 
per 100,000 inhabitants of ESC member countries declined from 273.0 (IQR 201.6 to 335.5) 
to 176.3 (IQR 150.0 to 238.0) (FIGURE 5.5). Declines exceeded 45% in Poland and Romania 
and only in Libya was an increase recorded from 268.1 in 1990 to 289.2 in 2017. 
 
5.1.2 Incidence of stroke 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 National statistics: In 2017, there were 2.3 million new cases of stroke in the 54 ESC 
member countries with data available. The median age-standardised number of new cases 
per 100,000 inhabitants of each member country was 143.4 (IQR 100.5 to 180.5). Stroke 
numbers for women and men were greatest across E Europe and N Africa (FIGURES 6 and 
7), ranging from 82.8 per 100,000 inhabitants in Italy to 213.4 per 100,000 inhabitants in 
Egypt (Supplementary Figures S5.7 and S5.8).   
 Stratification by sex: New cases of stroke across ESC member countries were shared 
almost equally between women and men (1.2 million vs. 1.1 million). However, the median 
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age-standardised rate per 100,000 people was lower in women than men (130.3 (IQR 90.5 
to 166.4) vs 159.9 (IQR 111.0 to 190.7)) (Supplementary Figures 5.7 and S5.8).   
 Stratification by national income status: The median age-standardised incidence of stroke 
per 100,000 people was higher in middle-income countries compared with high-income 
countries (179.7 (IQR 161.8 to 190.7) vs 101.8 (IQR 94.4 to 131.9)) for both women and 
men (FIGURE 5.8). In middle income countries, the incidence ranged from <120 in Armenia 
and Kyrgyzstan to >200 in Romania and Egypt while in high income countries it ranged 
from <85 in Switzerland and Italy to >190 in Latvia and Lithuania. 
 Time series data: Between 1990 and 2017, the median age-standardised incidence of 
stroke per 100,000 inhabitants of ESC member countries declined from 172.9 (IQR 133.8 
to 211.3) in 1990 to 143.4 (IQR 100.5 to 180.5) in 2017 (FIGURE 5.9).  This was reflected in 
national data which showed variable declines in age standardised stroke rates for all ESC 
member countries except Libya, Lithuania and Egypt. In Portugal the 52% decline in stroke 
rate exceeded that of all other ESC member countries. 
 
5.1.3 Incidence of PVD 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 National statistics: In 2017, there were 2.2 million new cases of PVD in the 54 ESC member 
countries with data available. The median age-standardised number of new cases per 
100,000 inhabitants of each member country was 132.2 (IQR 126.2 to 136.2), with 
incidence rates lowest in Norway and highest in Denmark.   
 Stratification by sex: New cases of PVD were distributed evenly between the sexes with 
women and men each contributing 1.1 million cases in 2017. With age-standardisation, 
however, the median incidence per 100,000 people was lower in women compared with 
men  (124.4 (IQR 110.6 to 133.6) vs 135.9, (IQR 123.7 to 157.9)) (FIGURE 5.10 and 5.11).   
 Stratification by national income status: The median age-standardised incidence of PVD 
per 100,000 people was similar in middle-income and high-income countries (133.1 (IQR 
127.3 to 135.9) vs 130.6 (IQR 125.8 to 136.4)) (Supplementary Figure S5.9).  In middle-
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income countries, the incidence ranged from 118.8 in Albania to 141.0 in Libya while in 
high-income countries it ranged from 89.8 in Norway to 177.7 in Denmark. 
 Time series data: Between 1990 and 2017, the median age-standardised incidence of PVD 
per 100,000 people remained relatively stable at 132.2 (IQR 126.2 to 136.2) in 1990 and 
136.8 (IQR 130.8 to 154.5) in 2017 (Supplementary Figure S5.10). However, in 43 of the 
54 countries there was a variable increase in the age-standardised incidence of PVD, 
greatest in the UK which experienced an increase of 32%.   
 
5.1.4 Incidence of atrial fibrillation 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 National statistics: In 2017 there were 0.75 million new cases of AF in the 54 ESC member 
countries with data available . The median age-standardised number of new cases per 
100,000 inhabitants of each member country was 44.3 (IQR 39.7 to 47.5), ranging from 
22.1 cases in Turkey to 63.9 cases in Sweden  
 Stratification by sex: In 2017, women and men accounted for similar numbers of new 
cases of AF (0.35 million vs. 0.40 million) but median age-standardised rates per 100,000 
people were lower for women compared with men (35.0 (IQR 32.8 to 38.4) vs 54.3 (IQR 
49.3 to 59.4)) (FIGURE 5.12 and 5.13).  . 
 Stratification by national income status: The median age-standardised incidence of AF per 
100,000 people was lower in middle-income countries compared with high-income 
countries (49.6 (IQR 27.5 to 51.8) vs 59.3 (IQR 56.3 to 65.2)) in both men and women 
(FIGURE 5.14).   The age-standardised incidence per 100,000 people in middle-income 
countries ranged from 22.1 in Turkey to 45.1 in Ukraine, and in high income countries from 
33.5 in Portugal to 63.9 in Sweden. 
 Time series data: Between 1990 and 2017, the median age-standardised incidence of AF 
per 100,000 people remained relatively stable at 44.7 (IQR 39.9 to 51.5) in 1990 and 44.3 
(IQR 39.7 to 47.5) in 2017 (Supplementary Figure S5.11). In just over half of the ESC 
member countries a variable, usually small, increase in the age-standardised incidence of 
AF was recorded, greatest for Portugal where the incidence increased by 45%. 
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5.2 Prevalence of CVD 
Data:  
Data source:  
Completeness:  
Year of data: 
 
Disease prevalence is the proportion of cases in the population at a given time. It indicates 
how widespread the disease is. 
 
 National statistics: In 2017, there were 108.7 million people living with CVD in the 54 ESC 
member countries with data available. The median age-standardised prevalence per 
100,000 inhabitants of each member country was 6594.9 (IQR 6183.6 to 7107.8), ranging 
from 5253.6 in Norway to 8765.6 in Bulgaria (FIGURE 5.15).    
 Stratification by sex: In 2017, there were more women than men living with CVD across 
ESC member countries (55.7 vs 52.9 million). The median age-standardised prevalence 
rates per 100,000 people were lower for women compared with men (6190.4 (IQR 5529.3 
to 6841.7 vs 7250.4 (IQR 6661.1 to 7793.7)) (Supplementary Figures S5.12- S5.15).Rates 
per 100,000 for women ranged from 4420.9 in Norway to 8128.0 in Czech Republic and for 
men from 6156.4 in Cyprus to 9673.6 in Bulgaria.  
 Stratification by national income status: The median age-standardised prevalence of CVD 
per 100,000 inhabitants was higher in middle-income countries compared with high-
income countries (7022.2 (IQR 6561.5 to 7353.9) vs 6245.0 (IQR 5785.1 to 6910.6) in both 
women and men (FIGURE 5.16). The age-standardised prevalence per 100,000 people in 
middle-income countries ranged from 5976.2 in Moldova to 8765.7 in Bulgaria, and in high 
income countries from 5253.6 in Norway to 8457.2 in Czech Republic. 
 Time series data: Between 1990 and 2017, the median age-standardised prevalence of 
CVD per 100,000 people remained relatively stable at 7139.4 (IQR 6689.8 to 7571.9) in 
1990 and 7022.2 (IQR 6561.5 to 7353.9) in 2017 (FIGURE 17). Modest increases in 
prevalence were seen in all but 7 countries (Libya, Egypt, Georgia, Russia, Lithuania, 
Azerbaijan, Bosnia and Herzegovina) peaking in Portugal where the prevalence increased 
by 27% over the 27 year period.  
 
5.2.1 Prevalence of IHD 
Data:  
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Data source:  
Completeness:  
Year of data: 
 
 National statistics: In 2017, there were 34.9 million people living with IHD in the 54 ESC 
member countries with data available. The median age-standardised prevalence per 
100,000 inhabitants of each member country was 2270.4 (IQR 1508.3 to 2564.5) ranging 
from 1156.4 in Portugal to 3000.3 in Egypt. In both women and men prevalence was higher 
in east European and north African countries compared with west European countries. 
(FIGURES 5.18 and 5.19). 
 Stratification by sex: In 2017, there were fewer women living with IHD in ESC member 
countries compared with men (16.2 vs 18.7 million). Median age-standardised prevalence 
rates per 100,000 people were lower for women compared with men (1894.7 (IQR 1049.4 
to 2127.1) vs 2664.9 IQR 2018.5 to 3068.1)) (Supplementary Figures S5.16 and S5.17). 
Rates for women ranged from 873.2 in Portugal to 8128 in Morroco and for men from 
1507.5 in Portugal to 3677.2 in Belarus.  
 Stratification by national income status: The median age-standardised prevalence of IHD 
per 100,000 inhabitants was higher in middle-income countries compared with high-
income countries (2502.7 (IQR 2270.4 to 2640.0) vs 1526.6 (IQR 1396.3 to 2386.9)) in both 
women and men (FIGURE 5.20). In middle-income countries age-standardised prevalence 
per 100,000 inhabitants ranged from 5976.2 in Moldova to 8765.7 in Bulgaria, and in high 
income countries from 5253.6 in Norway to 8457.2 in Czech Republic. 
 Time series data: Between 1990 and 2017, the median age-standardised prevalence of IHD 
per 100,000 people showed a small decline from  2481.6 (IQR 1868.6 to 2810.5) in 1990 to 
2270.4 (IQR 1508.3 to 2564.5) in 2017 (FIGURE 5.21). Variable, usually small, declines in 
the age-standardised prevalence of IHD per 100,000 people were recorded in all ESC 
member countries, except Libya and Syria.  
 
5.2.2 Prevalence of stroke 
Data:  
Data source:  
Completeness:  
Year of data: 
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 National statistics: In 2017, there were 20.4 million people living with stroke in the 54 ESC 
member countries with data available. The median age-standardised prevalence of stroke 
per 100,000 inhabitants of each member country was 1275.5 (IQR 916.8 to 1551.5), 
ranging from 570.2 in Italy to 1869.4 in Latvia. In both women and men prevalence was 
higher in east European and north African countries compared with west European 
countries. (FIGURES 5.22 and 5.23).   
 Stratification by sex: In 2017 there were more women than men living with stroke (11.4 
vs 9.1 million) across ESC member countries. However, with age-standardisation, median 
prevalence rates per 100,000 people were lower for women compared with men (1272.1 
(IQR 878.2 to 1505.1) vs 1322.2 (IQR 970.6 to 1638.6)) (Supplementary Figures S5.18 and 
S5.19). Rates for women ranged from 539.9 in Italy to 1889.7 in Egypt and for men from 
606.8 in Italy to 2021.9 in Latvia.  
 Stratification by national income status: The median age-standardised prevalence of 
stroke per 100,000 people, was higher in middle-income countries compared with high-
income countries (1542.0 (IQR 1364.4 to 1727.7) vs 941.9 (IQR 873.9 to 1255.3)) for both 
women and men (FIGURE 5.24). In middle-income countries age-standardised prevalence 
per 100,000 inhabitants ranged from 1166.4 in Armenia to 1798.2 in Serbia, and in high 
income countries from 570.2 in Italy to 1869.4 in Latvia. 
 Time series data: Between 1990 and 2017, the median age-standardised prevalence of 
stroke per 100,000 people showed a small decline from 1405.4 (IQR 1027.5 to 1705.7) in 
1990 to 1275.5 (IQR 916.84 to 1551.46) in 2017 (FIGURE 5.25). Declines in the prevalence 
of stroke occurred in all but 15 ESC member countries and exceeded 35% in Estonia and 
Portugal. In Azerbaijan and Bosnia and Herzegovina, however, prevalence increased by 
over 15%.  
 
5.2.3 Prevalence of PVD 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 National statistics: In 2017, there were 25.8 million people living with PVD in the 54 ESC 
member countries with data available. The median age-standardised prevalence of PVD 
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per 100,000 inhabitants of each member country was 1460.1 (IQR 1365.9 to 1572.5), 
ranging from 1060.7 in Norway to 2204.4 in Denmark. 
 Stratification by sex: In 2017 there were more women than men living with PVD (13.8 vs 
12.0 million) across ESC member countries. However, median age-standardised prevalence 
rates for PVD per 100,000 people were similar for women and men (1415.1 (IQR 1346.9 to 
1480.5) vs 1455.6 (IQR 1298.8 to 1844.9)) (Supplementary Figures S5.20 and S5.21). Rates 
for women ranged from 879.9 in Norway to 1856.1 in Denmark and for men from 1183.8 
in Russia to 2608.9 in Denmark. 
 Stratification by national income status: The median age-standardised prevalence of PVD 
per 100,000 people, was (1416.7 (IQR 1363.4 to 1460.7) in middle-income countries 
compared with 1552.0 (IQR 1396.5 to 1639.2) in high-income countries. In middle-income 
countries age-standardised prevalence per 100,000 inhabitants ranged from 1250.3 in 
Kyrgyzstan to 1528.7 in Libya, and in high income countries from 1060.7 in Norway to 
2204.4 in Denmark. 
 Time series data: Between 1990 and 2017, the median age-standardised prevalence of 
PVD per 100,000 inhabitants of ESC member countries was stable at 1468.2 (IQR 1381.8 to 
1869.7) in 1990 and 1460.1 (IQR 1365.9 to 1572.5) in 2017 37 countries recorded small 
declines in the age standardised prevalence of PVD  which exceeded 20% in UK, Italy and 
Norway. Increases in prevalence in 17 countries were always small, never exceeding 8% 
(Supplementary Figure S5.22).  
 
5.2.4 Prevalence of atrial fibrillation 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 National statistics: In 2017, there were 10.0 million people living with AF in the 54 ESC 
member countries with data available. Across all ESC member countries, the age-
standardised median prevalence of AF per 100,000 inhabitants was 571.8 (IQR 510.8 to 
622.7), ranging from 265.7 in Turkey to 806.1 in Sweden. 
 Stratification by sex: In 2017 there were fewer women than men living with AF (4.6 vs 5.4 
million) across ESC member countries . Median age-standardised prevalence rates for AF 
per 100,000 people were lower for women than men (436.8 (IQR 380.6 to 479.6) vs 752.5 
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(IQR 670.4 to 832.3)) (FIGURES 5.26, 5.27). Rates for women ranged from 262.9 in Turkey 
to 637.6 in Austria and for men from 269.8 in Turkey to 1108 in Sweden.  
 Stratification by national income status: Across all ESC member countries, the median 
age-standardised prevalence of AF per 100,000 people was lower in middle income 
countries compared with high income countries (531.3 (IQR 332.0 to 565.4) vs 608.7 (IQR 
572.6 to 690.9))in both women and men (FIGURE 28). In middle-income countries age-
standardised prevalence per 100,000 people ranged from 265.7 in Turkey to 603.7 in 
Ukraine, and in high income countries from 405.9 in Portugal to 806.1 in Sweden. 
 Time series data: Between 1990 and 2017, the median age-standardised prevalence of AF 
per 100,000 inhabitants of ESC member countries was stable at 589.5 (IQR 525.5 to 640.5) 
in 1990 and 571.75 (IQR 510.8 to 622.7) in 2017 (Supplementary Figure S5.23). Declines 
in age-standardised prevalence of AF, recorded in 26 countries, exceeded 20% in Italy and 
Portugal while increases, recorded in 28 countries, exceeded 15% in Luxembourg, Austria 
and Latvia.  
  
 
5.3 Disability-adjusted life years (DALYs) lost to CVD 
Data:  
Data source:  
Completeness:  
Year of data: 
 
Disability-adjusted life-years combine information regarding premature death (years of life 
lost) and disability caused by the CVD (years lived with CVD) to provide a summary measure 
of health lost due to that condition. One DALY can be thought of as one lost year of 
‘healthy’ life. The sum of these DALYs across the population, or the burden of disease, can 
be thought of as a measurement of the gap between current health status and an ideal 
health situation where the entire population lives to an advanced age, free of disease and 
disability. It allows comparison of the overall health and life expectancy of different 
countries. 
 
 National statistics In 2017, the median number of age standardised DALYS lost to CVD, 
was 4530 (IQR 2178.8 to 6462.8) per 100,000 inhabitants of ESC member countries, 
ranging from <1600 in Switzerland, Israel and France to >10,000 in Ukraine and Egypt 
(FIGURE 29, 30). IHD and stroke were the major contributors to DALYS lost to CVD, 
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accounting for ~54% and ~28%, respectively. PVD and AF together accounted for less than 
2.5% of DALYS lost to CVD 
 Stratification by sex: Median age-standardised DALYS lost to CVD were 3219.4 (IQR 1596.8 
to 5323.6) per 100,000 people for women, ranging from 1114.5 in France to 7657.3 in 
Morroco. For men the median number of DALYS per 100,000 people lost to CVD was 
almost twice as high (5925.1 (IQR 2810.4 to 8124.4)) ranging from 1938.1 in Switzerland 
to 15077.2 in Ukraine (Supplementary figures S5.24 and S5.25). IHD was the major 
contributor to the difference between women and men with a nearly three-fold difference 
in median values for lost DALYS: 1384.2 (IQR 614.5 to 2422.6) vs 3144.5 (IQR 1513.3 to 
5261.2) per 100,000 people.  For stroke, however, DALYS lost were more comparable 
between the sexes at 951.3 (IQR 481.1 to 1729.5) vs 1254.8 (IQR 611.6 to 2426.2).  
 Stratification by national income status: The median number of age-standardised DALYS 
per 100,000 people lost to CVD was considerably higher in middle-income countries 
compared with high income countries (7519.6 (IQR 5654.5 to 8114.5) vs 2235.3 (IQR 
1895.5 to 3602.1)) in both women and men (FIGURE 31). IHD and stroke contributed 
equally to the difference with the median number of age-standardised DALYs lost to IHD 
3910.8 (IQR 2787.5 to 4770.5) per 100,000 inhabitants of middle income countries 
compared with 1041.5 (IQR 797.1 to 1910.1) per 100,000 inhabitants of high-income 
countries. For stroke the difference was 2182.5 (IQR 1517.3 to 2491.2) DALYS per 100,000 
people lost in middle income countries compared with 545.9 (IQR 488.5 to 854.6) in high 
income countries. 
 Time series data:  Between 1990 and 2017 age-standardised DALYs lost to CVD per 
100,000 inhabitants of ESC member countries declined, from 7541.6 (IQR 5244.2 to 
9277.5) to 4530.0 (IQR 2178.8 to 6462.8) (FIGURE 32). Declines were >60% in Ireland, 
Portugal, Denmark, Norway and Israel with only Azerbaijan and Belarus recording an 
increase. IHD and stroke contributed importantly to the declines in DALYS lost to CVD, with 
median age-standardised values for IHD falling from 7541.63 (IQR 5244.2 to 9277.5) to 
4530.0 (IQR 2178.8 to 6462.8) per 100,000 inhabitants of ESC member countries. Data for 
stroke were similar with age-standardised DALYS lost falling from a median value of 2035.0 
(IQR 1222.7 to 3000.4) to 1140.8 (IQR 536.7 to 2011.0) per 100,000 inhabitants of ESC 
member countries. Only Ukraine, Azerbaijan, Kyrgyzstan Libya and Belarus recorded an 
 49 
increase in age-standardised DALYs lost to IHD and only Azerbaijan an increase in DALYs 




 Declines in the age-standardised incidence of CVD the last 27 years have been small and, 
in 11 ESC member countries, non-existent.  
 The age-standardised incidence of CVD’s major components, IHD and stroke, have both 
shown a downward trend during the last 27 years. Downward trends in disease prevalence 
have been small 
 Differences between women and men in the crude incidence and prevalence of IHD and 
stroke were small but with age-standardisation rates were consistently lower in women.  
 The age-standardised incidence and prevalence of IHD and stroke were higher in middle-
income compared with high-income ESC member countries. 
 IHD and stroke accounted for 82% of DALYS lost to CVD in ESC member countries 
 Age-standardised DALYS lost to CVD have been in steep decline the last 27 years, with just 
2 middle-income countries recording an increase. 
 DALYS lost to CVD were almost twice as high in men compared with women and three 
times as high in middle-income compared with high-income ESC member countries. 
 The age-standardised incidence and prevalence of AF tended to be lower in women 
compared with men and in middle-income compared with high-income ESC member 
countries. Data for PVD were mixed with only small differences by sex and national income 
status.  
 Across all ESC member countries, age-standardised incidence and prevalence rates of AF 
and PVD have remained stable the last 27 years. 
 
5.5 Comment 
In the current 2019 iteration of CVD statistics, granularity of disease burden has been 
enhanced by inclusion of data on key CVD phenotypes including IHD, stroke, PVD and AF.  The 
data show small but welcome declines in the age-standardised incidence and prevalence 
rates of IHD and stroke during the last 27 years although rates for PVD and AF were more 
stable. Less welcome were the persisting inequalities in disease burden by sex and national 
income status. These inequalities were vividly reflected in the DALYS lost to CVD which in 
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2017 were almost twice as high in men compared with women and three times as high in 
middle-income compared with high-income ESC member countries. Men are often the 
principle wage-earners and the negative effects of IHD and stroke on absenteeism, lost 
productivity and life expectancy must impact substantially on family welfare and national 
prosperity. The Atlas shows how impact falls hardest on middle income countries that can 
least afford the loss of agricultural and industrial manpower. These same countries are often 
further disadvantaged in their ability to meet the costs of contemporary cardiovascular care 
such that healthcare delivery is variably undermined by inadequate staffing levels and limited 
infrastructure. Prevention of CVD is perhaps less affected by these resource constraints yet 
plays as important a role as the treatment of established disease in reducing its prevalence 
and socio-economic impact67 68. The same primary and secondary prevention strategies that 
have guideline indications 69 need concerted application across all ESC member countries.  
 
The AF and PVD data included in the current report need cautious interpretation. Under-
diagnosis of these disorders is commonplace (9)70, particularly when the availability of ECG 
monitoring and non-invasive imaging technology is limited. This may account for the 
prevalence of both disorders being lower in middle-income than high-income countries. 
Addressing under-diagnosis of AF and PVD in middle-income countries provides a potentially 
important means of reducing the high stroke rate by targeting individuals for anti-thrombotic 




6. Cardiovascular disease mortality 
 
 
Mortality data are commonly used in disease surveillance. Death from a disease can provide 
an indication of its burden within a population, particularly for chronic conditions, such as 
CVD.  
 
In addition, death data are commonly one of the most reliable. Death reporting is often a 
mandatory part of a country’s vital statistics system. In most countries, health authorities 
require that each death in the population be reported, including a record of cause of death. 
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These records can then be compiled in order to produce mortality measures for the 
population, including absolute number of deaths and rates that adjust for population size and 
distribution. 71  
 
However, although death registration systems are universal, they can be of widely differing 
quality and completeness. In most developed countries, this system is relatively complete, 
and the mortality rates calculated from the data are reasonably accurate. However, in many 
less-developed countries, health record systems are very incomplete. Many deaths may go 
unreported, particularly if the occur outside of the health system. 72 73 
 
The WHO deem that most of the ESC member countries have high quality death records 
with relatively high levels of usability accompanied by low levels of garbage coding. 8 This 
makes mortality data an informative way to describe the burden of CVD throughout the 
region.  
 
6.1 Number of deaths 
Data: Total numbers of deaths by cause, gender, latest available year; WHO Mortality Database 
http://apps.who.int/healthinfo/statistics/mortality/whodpms/; Completeness: Europe 37/39; Non-European former Russian Republics 
9/9; E Med & N Africa 1/8. Year of data: 2007–17. 
 
The number of deaths from a disease, demonstrates the absolute burden of that disease 
within a population. Although presenting just the total number of deaths of a disease limits 
our ability to compare between populations, it does allow us to compare between diseases 
in the same population.71 72 
 
Despite sustained declines in CVD mortality in many countries across Europe, cardiovascular 
diseases have remained the most common cause of death within the region.74 75 76 In some 
individual countries, however, improvements in CVD prevention and treatment have led to 
cancer becoming the most common cause of death.76 
  
 National Statistics stratified by sex Cardiovascular disease remains the most common 
cause of death within ESC member countries as a whole, accounting for 1,902,281 deaths 
in males and 2,211,729 deaths amongst females, in the most recent year of available data 
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(FIG 6.1). These equate to 39% and 47% of all deaths in men and women respectively. 
Ischaemic Heart Disease (IHD) accounts for 44% of these CVD deaths in males and 38% of 
CVD deaths in females, with stroke the second most common cause of CVD deaths, 
accounting for 21% of all CVD deaths in males and 26% of all CVD deaths in females.  
 CVD versus cancer Although the total number of CVD deaths across ESC member countries 
far exceed the number of cancer deaths for both sexes (men = 1,118,008; women = 
887,688), cancer now causes more deaths than CVD in a number of individual countries. 
These include, Belgium, Denmark, France, Ireland, Israel, Luxembourg, Netherlands, 
Norway, Portugal, San Marino, Slovenia, Spain, Switzerland and the UK for men, along with 
Denmark, Israel, Netherlands, San Marino and the UK for females. 
 National income status. In both women and men a greater proportion of deaths are 
caused by CVD in middle-income countries compared with high-income countries (FIG 6.2). 
All countries in which cancer has become the most common cause of death are high 
income, with this reflected in the higher median proportion of all deaths caused by CVD in 
middle income countries (males = 47%, females = 57%) than high income countries (males 
= 33%, females = 35%).   
 
6.2 Premature cardiovascular disease mortality  
Data: Number of deaths under 70 years by cause, gender; Data source: WHO Mortality Database http://apps.who. 
int/healthinfo/statistics/mortality/whodpms/. Completeness: Europe 37/39; Non-European former Russian Republics 9/9; E Med & N 
Africa 1/8; Year of data: latest available from Year of data: 2007–17. 
 
CVDs develop with age and as populations live longer we expect such aging-associated, or 
age-related, diseases to increase.77 Individuals dying at younger ages from CVD are of greater 
concern, as we know that such diseases are preventable at these ages. Such deaths are 
considered premature, with premature mortality considered an important measure, as it 
demonstrates unfulfilled life expectancy. 78 
 
Although there is no definitive definition of premature death, with deaths in those younger 
than either 65 or 75 years often used,76 79 here we present deaths before the age of 70 years, 
in order to align with WHO targets presented later in the chapter.40 80 
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 National statistics stratified by sex Compared with deaths for all ages within the ESC 
region, CVD accounts for a smaller proportion of premature deaths (< 70 years) in both 
males (33%) and females (29%). This corresponds to 322,693 deaths amongst females and 
698,909 deaths amongst males.(FIG 6.3) 
 CVD versus cancer CVD remains the most common cause of premature death in the region 
amongst men but this is not the case for women amongst whom cancer kills more 
individuals than any other disease (n = 359,046). It should be noted, however, that the 
number of males dying from cancer before the age of 70 is higher than for females (n = 
505,633) reflecting the much lower risk of overall and CVD specific premature mortality 
amongst women.  
 National income status  Disparities between high and middle income countries in the 
proportion of premature deaths caused by CVD are greater for females, with a median of 
35% of all premature deaths caused by CVD in middle income countries, compared to 16% 
for high income countries for women; whereas a median of 36% of all premature deaths 
in men are caused by CVD in middle income countries compared to 24% in high income 
(FIG 6.4).  
 
6.3 Potential years of life lost to cardiovascular disease 
Data: Potential years of life lost (PYLL) by cause, by sex, latest available year; Data source: European WHO Mortality Database 
http://apps.who.int/healthinfo/statistics/mortality/whodpms/; Completeness: Europe 37/39; Non-European former Russian 
Republics 9/9; E Med & N Africa 1/8; Year of data: 2017. 
Potential years of life lost (PYLL), is a summary measure of premature mortality. PYLL 
estimates the years of potential life lost due to premature death. PYLL takes into account 
the age at which deaths occur, giving greater weight to deaths at a younger age and lower 
weight to deaths at older age.81 
PYLLs are calculated from the number of deaths multiplied by a standard life expectancy at 
the age at which death occurs. This allows us to measure the proportion of total PYLL in a 
population caused by specific diseases.81 
 National statistics stratified by sex CVD accounts for 38,376,581 of potential years of life 
lost (PYLLs) amongst males within the ESC region and 28,002,314 amongst females, making 
up 34% of all years lost for males and 37% for females. In comparison, cancer accounts for 
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22% of PYLLs in males, equivalent to 25,488,618 PYLLs, and 25% of PYLLs in females; 
18,654,902 PYLLs 
 Stratification by national income status  On average CVD accounts for a greater 
proportion of PYLLs in middle income than high income countries in both males (median 
% of PYLLs high income = 28%, middle income = 39%) and females (high income = 29%, 
middle income = 46%) (FIG 6.5). The opposite is true for cancer, for which the median 
proportion of PYLLs was higher than from CVD in high income countries for both sexes 
(cancer PYLLs % of total PYLLs males = 35%, females = 34%), whereas within middle income 
countries it was much lower (males = 18%, females = 19%). Large variations can be seen 
between individual countries, with the lowest proportion of country specific CVD PYLLs 
similar between high and middle income countries. Eight middle income countries (38%) 
had more than 40% of total PYLLs caused by CVD in males compared to only one high 
income country (Latvia = 43%). In females, five middle income countries (24%) had more 
than half (50%) of total PYLLs caused by CVD, whereas no high income countries did. 
 
6.4 Cardiovascular disease crude mortality rates 
Data: Crude mortality rates (deaths per 100 000) from IHD and stroke, all ages, by sex, 1980 to 2014; Data source: European WHO 
Mortality Database http://apps.who.int/healthinfo/statistics/mortality/whodpms/; Completeness: Europe 37/39; Non-European 
former Russian Republics 9/9; EMed&NAfrica 1/8.Year of data: latest 2007–17. 
 
Using absolute mortality measures, such as number of deaths or total PYLLs, can be 
misleading as they do not account for population size. Comparing between countries and over 
time should, therefore, take account of differences and changes in populations. The simplest 
way to do this is to calculate a crude rate, which adjust number of deaths by population size. 
These rates are commonly expressed per 100,000 of the population. 82 
 
 National statistics stratified by sex  Median crude mortality rates for CVD, that adjust for 
population size, are greater for females than males in both high income (female CVD crude 
mortality rate = 332/100,000 individuals, males = 303/100,000) and middle-income 
countries (female = 530/100,000, males = 488/100,000). The steep downward CVD 
mortality gradient from east to west across Europe is particularly stark for premature 
mortality in women and men aged <70 (FIGS 6.6 and 6.7). In general, country level crude 
deaths decrease with increasing gross domestic product (GDP) and relative current health 
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care expenditure (CHE). However, this relationship is affected by greater variation at lower 
GDP and CHE figures, with some countries demonstrating low crude rates despite lower 
values for both (supplementary figures 6.1-6.4). 
 Stratification by national income status   Five of the 19 middle income countries for which 
we obtained rates, had crude CVD mortality rates for males below 303 deaths per 100,000 
individuals, equivalent to the median crude death rate for high income countries 
(Kazakhstan = 214/100,000, Kyrgyzstan = 279/100,000, Syria = 175/100,000, Tunisia = 
59/100,000 and Turkey = 207/100,000). Conversely five of 30 high income countries with 
recent data, reported crude CVD deaths rates above 488/100,000, equivalent to the 
middle income median (Croatia = 499/100,00, Estonia = 523/100,000, Hungary = 
596/100,000, Latvia = 724/100,000 and Lithuania = 712/100,00). (Supplementary fig 6.5). 
– These differences are more stark when we consider crude rates for premature 
mortality (FIGS 6 and 7),  with only one middle income country reporting a crude CVD 
death rate for males below the high income median of 74/100,000 (Tunisia = 
18/100,000) and only three high income countries reporting a premature mortality 
CVD rate amongst males of higher than 193/100,000, the middle income country 
median (Hungary = 233/100,000, Latvia = 297/100,000, Lithuania = 255/100,000) (FIG 
6.8). 
– Disparities were similar amongst females for deaths amongst all ages, with Croatia 
(608/100,000), Estonia (679/100,000) Hungary (681/100,000) Latvia (893/100,00) and 
Lithuania (868/100,000) all high income countries with crude rates above the middle 
income country median of 530/100,000 and Azerbaijan (324/100,000), Egypt 
(290/100,000), Kazakhstan (174/100,000), Kyrgyzstan (270/100), Syria (152/100,00), 
Tunisia (52/100,000) and Turkey (211/100,000) all middle income countries with 
crude rates below the high income median (303/100,000).  
– For premature mortality crude rates, Latvia (108/100,000) was the only high income 
country demonstrating crude CVD mortality rates for females under 70 years, higher 
than the middle income median of 102/100,000 and Tunisia (10/100,000) was the only 
middle income country reporting a CVD crude mortality rate lower than the high 
income median of 27/100,000.  
– For both sexes associations can be seen between CVD crude deaths rates for those 
under the age of 70 years and both GDP and CHE (supplementary figures 6.6-6.9).  
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6.5 Cardiovascular disease age-standardized mortality rates 
Data: Age-standardized mortality rates (deaths per 100 000) from IHD and stroke, all ages, by sex, 1980 to 2014; Data source: European 
WHO Mortality Database http://apps.who.int/healthinfo/statistics/mortality/whodpms/; Completeness: Europe 37/39; Non-European 
former Russian Republics 9/9; E Med & N Africa 1/8.Year of data: latest 2007–17. 
 
For aging-associated diseases such as CVD, the numbers of deaths per 100,000 population are 
influenced by the age distribution of the population. A population with a greater distribution 
of individuals in older age would be expected to experience a greater number of CVD deaths. 
In order to compare between populations, as well as adjusting for population size, as with 
crude rate above, we often calculate age standardised rates, which adjust for population 
distribution as well.82  
 
Age-standardised mortality rates adjust for differences in the age distribution of populations 
by applying the observed age-specific mortality rates for each population to a standard 
population.82 A comparison of age-standardised mortality rates for different countries will be 
unaffected by any differences in the age-distributions of their populations. This can be useful 
for comparing between countries in Europe as life expectancy can vary by a large amount 
across the region.82 83 
 
Age standardised mortality rates calculated for each country can be thought of as the rate 
that the countries would have if they had the same population distribution as the standard 
population. The recommended standard population used for calculating ASMRs within 
Europe is the European Standard Population (ESP).83 84 
 
 In contrast to crude rates, age standardised mortality rates (ASMRs), that adjust for both 
population size and distribution, are greater for males than females in both high income 
(males CVD crude death rate = 392/100,000 individuals, females = 281/100,000) and 
middle-income countries (male = 880/100,000, females = 706/100,000) (FIG 6.9) 
 In both males and females ASMRs for CVD are higher in middle-income countries 
compared with high income countries (FIG 6.9) ASMRs are closely correlated with GDP and 
CHE, with those countries with low GBD or low CHE demonstrating higher age standardised 
rates (FIG 6.10-6.13). There is some suggestion of plateauing of ASMRs with increasing 
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GDP and CHE, with those countries above median values of both measures demonstrating 
much less variation in ASMRs than those countries below the median. 
 
6.6 Achieving global mortality targets 
Data: Crude mortality rates (deaths per 100 000) from IHD and stroke, all ages, by sex, 1980 to 2014; Data source: European WHO 
Mortality Database http://apps.who.int/healthinfo/statistics/mortality/whodpms/; Completeness: Europe 37/39; Non-European former 
Russian Republics 9/9; EMed&NAfrica 1/8.Year of data: latest 2007–17. Potential years of life lost (PYLL) by cause, by sex, latest available 
year; Data source: European WHO Mortality Database http://apps.who.int/healthinfo/statistics/mortality/whodpms/; Completeness: 
Europe 37/39; Non-European former Russian Republics 9/9; E Med & N Africa 1/8; Year of data: latest between 2017. 
 
The WHO Global monitoring framework on noncommunicable disease80 tracks 
implementation of the NCD global action planError! Bookmark not defined. through monitoring and 
reporting on the attainment of the 9 global targets for NCDs, by 2025, against a baseline in 
2010. Target 1 relates to mortality and requires countries to achieve a 25% relative reduction 
in the overall mortality from cardiovascular diseases, cancer, diabetes, and chronic 
respiratory. The WHO Global monitoring framework emphases premature mortality, by 
focusing on deaths under the age of 70 years.80   
 
 High income countries have demonstrated median relative reductions in crude mortality 
rates for those aged under 70 years, of 11% for males and 9% for females since 2010, or 
the nearest available year of data. Reductions amongst females in middle income countries 
(8%) are similar but a much lower median reduction is found in middle income countries 
for males (2%) (FIG 6.14). 
 Although this is pleasing in reference to the WHO targets, as the most recent data for 
countries generally come from 2017 or earlier, it is alarming to note that a number of 
countries have demonstrated increases in crude premature CVD mortality rates over this 
time in males (Greece, Italy, Malta, Poland, Portugal and Spain) and females (Israel, Italy, 
Malta, Poland, Portugal and Spain) (FIGS 6.15 and 6.16). 
 Six of the 13 middle income countries demonstrated an increase in crude premature 
mortality rates from 2010 to the most recent year of data in males (Bulgaria, Egypt, 
Georgia, Romania, Serbia, Turkey) and four did so for females (Bulgaria, Egypt, Georgia, 
Turkey) (FIG 6.17 and 6.18). 
 Although a relationship can be seen between decreasing relative reductions in crude 
mortality rates for those under 70 years and both increasing GDP and increasing current 
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health care expenditure (CHE), there is wide variation in mortality outcomes amongst 
those countries with lower GDP and CHE. For example, the country with the greatest 
relative decrease in crude mortality rates (Kazakhstan, males = -45%; females = -50%) and 
the country with the greatest increases (Georgia, males = +43%; females = +40%) are both 
middle income countries with similar GDP and CHE figures. 
 Using PYLLs, adjusted for population size, we find a median decrease in high income 
countries of just over 6% for both males and females, whereas middle income countries 
demonstrate a median decrease of 2.4% for females and a 2.2% increase in males (FIG 
6.19). 
 Five high-income countries (17%) demonstrated an increase of PYLLs in males (Germany, 
Greece, Iceland, Lithuania and Malta) with Greece, Lithuania and Malta also doing so for 
females. This compared to fourteen out of twenty-four middle-income countries that 
demonstrated an increase in PYLLs in males and eight for females. 
 As with crude premature mortality rates, greater variation in change in PYLL is found at the 
lower levels of both GDP and CHE, with countries with the highest and lowest percentage 
changes in PYLL found amongst those in the lower half of both measures. 
 
6.7 Summary  
 Despite sustained declines in CVD mortality in many countries across Europe, it remains 
the most common cause of death within the region 
 
 Ischaemic Heart Disease (IHD) accounts for 44% of these CVD deaths in males and 38% of 
CVD deaths in females 
 
 CVD is also the most common cause of premature (age <70 years) death in the region 
amongst men but this is not the case for women amongst whom cancer kills more 
individuals than any other disease 
 
 There are large disparities between high and middle income countries in the proportion of 
premature deaths caused by CVD. For women in middle income countries a median of 35% 
of all premature deaths are caused by CVD compared with 16% in high income countries. 
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For men the respective rates are 36% in middle income countries compared with 24% in 
high income countries.  
 
 CVD accounts for 34% of potential years of life lost (PYLLs) for men and 37% for women. In 
comparison, cancer accounts for 22% of PYLLs in men and 25% in women 
 
 CVD accounts for a greater proportion of PYLLs in middle income than high income 
countries in both men and women but the opposite is true for cancer for which the 
proportion of PYLLs from cancer was higher than from CVD in high income compared with 
middle income countries. 
 
 In contrast to crude rates per million people, age standardised mortality rates (ASMRs), 
that adjust for both population size and distribution, are greater for men than women in 
both high income and middle-income countries 
 
 The WHO Target 1 is for a 25% reduction in CVD mortality by 2025 with reference to 2010. 
During this period crude mortality per million people in high income countries has fallen 
by 11% in men and 9% in women. Reassuring as this is, an alarming increase in crude CVD 
mortality has been recorded in a number of countries in both men (Greece, Italy, Malta, 
Poland, Portugal and Spain) and women (Israel, Italy, Malta, Poland, Portugal and Spain). 
In middle income countries women have shown an 8% reduction in mortality during the 
same period but in men the reduction has been by only 2%, making unlikely the 25% WHO 
target will be attained.  
 
6.8 Comment 
Cardiovascular disease remains the most common cause of death within ESC member 
countries and continues to be a major concern for health, social and economic services. 
Although more females than males die from CVD, higher age standardised mortality rates and 
premature mortality measures amongst men suggest that women are dying at older ages 
from cardiovascular diseases. Although females may experience some physiological 
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protection from CVD, particularly up until menopause,85 risk factor differences between the 
sexes may explain some of this inequality.  
  
The transition towards cancer as the most common cause of death in a number of high 
income countries, comes as a result of dramatic decreases in CVD mortality in the preceding 
30 to 40 years74 75, most likely due to both improved prevention and treatment.86 However, 
large inequalities in mortality across ESC members and recent worrying trends in both high 
and low income countries give us cause for concern. 
 
Not only do we find large variation in current measures for mortality but recent trends in 
premature mortality differ between ESC member countries. It is particularly worrying to note 
that a number of both high and middle income countries have demonstrated increases in 
crude premature mortality rates and population adjusted PYLLs in recent years, suggesting 
that they may struggle to obtain WHO targets of 25% reductions in premature mortality 
between 2010 and 2025.  
 
Further work should be done to understand why these inequalities exist. This should include 
improved and standardised surveillance on mortality and other epidemiological measures 
related to CVD within countries, as well investigation into the challenges countries face in 
implementing recommended preventive and treatment approaches.  
 
 
7. Cardiovascular healthcare delivery 
 
 
Strategies for treatment of CVD have complemented disease prevention strategies and 
lifestyle changes in delivering the declines in cardiovascular mortality that have been 
recorded in Western societies during the last 50 years.67 68 Increasingly, it has been 
technological interventions that have come to dominate contemporary treatment strategies 
and this trend is on a steep upward trajectory, bringing with it a financial burden that many 
countries can ill afford. Already the healthcare budget exceeds 10% of GDP in many Western 
countries87 and recent predictions are that novel medical technologies will be a more 
significant factor than population ageing in driving up costs during the next 50 years (4).88 
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Documenting human and capital resource statistics as they affect cardiovascular healthcare 
delivery in ESC member countries is, therefore, an important exercise for identifying where 
the shortfalls lie and determining what corrective action might be needed.  
 
7.1 Coronary disease 
 
7.1.1 Cardiologists   
Data:  
Data source:  
Completeness:  
Year of data: 
,  
 
 Human Resource Across all ESC member countries in the 2018/19 survey, there was a 
median of 80.9 (IQR 59.7 to 108.9) cardiologists per million people, with numbers ranging 
from <30 per million in UK, Ireland and Turkey to >250 per million in Italy , Greece and 
Republic of Georgia (FIGURE 7.1, FIG S7.1). 
 Women in Cardiology Women comprised 28% of cardiologists working in ESC member 
countries. Under-representation of women was greatest in Republic of Kosovo, UK and 
Ireland where women comprised <15% of the cardiac workforce compared with >70% in 
Latvia, Lithuania, Republic of Moldova and Armenia.  
 Stratification by National Income Status The median number of cardiologists per million 
inhabitants of middle income ESC member countries was lower compared with high 
income countries (63.0 (IQR 53.4 to 87.9) vs 90.8 (IQR 70.9 to 110.9)) (FIG S7.2). Female 
cardiologists comprised 32% of the workforce in middle income countries, compared with 
27% in high income countries. These averaged data, however, conceal considerable 
variation and the four ESC member countries in which >70% of cardiologists were women 
were evenly distributed between middle income (Armenia, Republic of Moldova) and high 
income (Lithuania, Latvia) countries. 
 
7.1.2  Catheter Laboratories and Diagnostic Angiography  
Data:  
Data source:  
Completeness:  
Year of data: 
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 Infrastructure A median of 2.9 (IQR 1.9 to 4.0) hospitals per million inhabitants of ESC 
member countries reported having facilities for cardiac catheterisation in the 2018/19 
survey (FIGURE 7.2). Provision ranged from <1 hospital per million in Ukraine, Republic of 
Moldova, Kyrgyzstan and Egypt to >4.5 in Switzerland, Austria, Greece Cyprus and Bulgaria. 
 Service Delivery A median of 4601.5 (IQR 3146.0 to 5516.4) diagnostic coronary 
angiograms per million people were performed across ESC member countries in 2017, or 
the most recent year that data were available, ranging from <1000 in Kyrgyzstan, Ukraine 
and Egypt to >7000 in Austria, Lithuania and Germany (FIGURE 7.3, S7.3).  
 Stratification by National Income Status The median number of hospitals per million 
inhabitants of ESC member countries that provided catheter laboratory facilities for 
diagnostic cardiac catheterisation was lower in middle income compared with high income 
countries (1.9 (IQR 1.5 to 3.7) vs 3.1 (IQR 2.2 to 4.3)) (FIG S7.4), although Bulgaria and 
Republic of Georgia were outliers among middle income countries in providing more than 
seven hospitals per million people, more than any of the high income ESC member 
countries. With fewer facilities for cardiac catheterisation, median numbers of diagnostic 
catheter procedures per million people were also lower in middle income compared with 
high income countries (2305.5 (IQR 1105.9 to 3757.5) vs 5234.8 (IQR 4195.6 to 5878.4)) 
although these averaged data concealed important differences with TFYR Macedonia, 
Bulgaria and Turkey among middle income countries performing more procedures than 
many high income countries (FIGURE 7.4). 
 
7.1.3 Percutaneous Coronary Intervention (PCI)  
Data:  
Data source:  
Completeness:  
Year of data: 
 
 Human Resource The 2018/19 survey showed a median of 13.4 (IQR 9.0 to 17.9) 
interventional cardiologists per million inhabitants of ESC member countries, with 
numbers ranging from <5 per million in Republic of Moldova, Azerbaijan, Romania, Egypt 
and Ukraine to >25 per million in Malta, Switzerland and Austria (FIGURE 7.5, FIGURE S7.5)  
). In Germany there were 53 interventional cardiologists per million people. 
 Infrastructure The median number of hospitals per million inhabitants of ESC member 
countries that offered a 24 hour/7 day facility for cardiac catheterisation was 1.8  (IQR 1.1 
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to 2.8), ranging from <1 hospital per million people in Egypt, Kyrgyzstan, Ukraine, Romania, 
Denmark, Republic of Moldova and Slovenia to >4 in Poland, Belgium, Cyprus and Bulgaria. 
 Service Delivery  
a) PCI  A median of 2046.8 (IQR 1477.8 to 2588.3) PCI procedures per million 
inhabitants of ESC member countries were reported in the 2018/19 survey 
(FIGURE 7.6). Numbers ranged from <500 procedures per million people in 
Kyrgyzstan, Ukraine and Azerbaijan to >3500 in Germany, Austria and Bulgaria.  
b) Primary PCI A median of 462.1 (IQR 346.4 to 624.2) primary PCI procedures per 
million inhabitants of ESC member countries were reported in the 2018/19 survey 
(FIGURE 7.7). Numbers ranged from <200 procedures per million people in 
Kyrgyzstan, Egypt, Azerbaijan and Ukraine to >1000 in Lithuania and Bulgaria (FIG 
S7.6). 
 Stratification by National Income Status The median number of interventional 
cardiologists per million inhabitants of ESC member countries reported in the 2018/19 
survey was lower in middle income countries compared with high income countries  (6.3 
(IQR 4.4 to 10.9 vs 15.1 (IQR 11.9 to 20.3)) (FIGURE 7.8) and there was further inequality 
in 24 hour/7 day catheter laboratory availability (1.4 (IQR 0.7 to 2.4) vs 2.0 (IQR 1.5 to 3.0)). 
Median numbers of PCI procedures per million inhabitants of ESC member countries 
reported in the 2018/19 survey were also lower in middle income compared with high 
income countries (943.8 (IQR 563.8 to 1715.3) vs 2453.5 (IQR 1781.0 to 2628.3)) (FIGURE 
7.9) but primary PCI numbers were more similar (428.2 (IQR 257.2 to 682.7) vs 462.1 (IQR 
382.5 to 600.1)) (FIG S7.7).  
 
7.2 Interventions to treat valvular heart disease 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 Infrastructure. In the 2018/19 survey, a median of only 0.8 (IQR 0.5 to 1.4) hospitals per 
million inhabitants of ESC member countries reported catheter laboratories equipped for 
structural heart interventions. Numbers ranged from <0.5 hospitals per million people in 
Kazakhstan, Kyrgyzstan, Republic of Moldova and Egypt to >3.0 in Italy and Switzerland. In 
Bosnia and Herzegovina and Republic of Kosovo there were no hospitals offering this 
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service and an additional 5 countries (Albania, Armenia, Azerbaijan, and Republics of 
Georgia  and Moldova) reported having performed no interventional aortic or mitral valve 
procedures despite availability of appropriately equipped laboratories. 
 Service Delivery.  
a) Transcatheter aortic valve implantation (TAVI) TAVI procedures were performed 
in all 43 ESC member countries that returned data except Albania, Azerbaijan, 
Bosnia and Herzegovina, Kyrgyzstan and Republics of Georgia, Kosovo and 
Moldova. A median of 25.5 (IQR 3.0 to 62.2) TAVI procedures per million 
inhabitants of ESC member countries were performed in 2017, or the most recent 
year that data were available, numbers ranging from <1 procedure per million 
people in Egypt and Serbia to >200 in Switzerland and Germany (FIGURE 7.10, 
FIGURE S7.8). 
b) Percutaneous repair of the mitral valve All of the 43 ESC member countries that 
returned data reported performing percutaneous mitral valve repair procedures 
with the exception of Albania, Armenia, Azerbaijan, Bulgaria, Estonia, Iceland, 
Serbia, TFYR Macedonia and Republics of Georgia, Kosovo and Moldova. A median 
of 2.7 (IQR 0 to 7.2) procedures per million people were performed across ESC 
member countries in 2017, or the most recent year that data were available, with 
Switzerland and Germany reporting  >40.  
 Stratification by National Income Status In the 2018/19 survey the median number of  
hospitals per million inhabitants of ESC member countries that had catheter laboratories 
equipped to treat structural heart disease was lower in middle income countries compared 
with high income countries (0.5 (IQR 0.3 to 0.7) vs 1.1 (IQR 0.7 to 1.7)) (FIGURE 7.11) 
Procedure rates were accordingly low in middle income countries where TAVIs were 
performed in only Egypt, Serbia, Kazakhstan, Macedonia, Bulgaria and Turkey while 
percutaneous mitral valve repairs were performed in only Romania, Kyrgyzstan, and 
Bosnia and Herzegovina (FIGURE 7.12). In high income countries procedure rates for TAVI 
and mitral valve repair were much higher, with median numbers per million people 45.0 
(IQR 28.1 to 71.0) and 5.1 (IQR 2.5 to 9.8) in 2017, or the most recent year that data were 
available. 
 
7.3 Electrophysiology, Ablations and Device Implants 
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Data:  
Data source:  
Completeness:  
Year of data: 
 
 Human Resource The 2018/19 survey identified a median of 4.4 (IQR 2.3 to 7.0) cardiac 
electrophysiologists per million people working in ESC member countries, ranging from <1  
in Egypt, Azerbaijan, Kyrgyzstan and Republic of Moldova to >10 in Sweden, Czech 
Republic, Italy, Greece, and Luxembourg. In Iceland there were >20 cardiac 
electrophysiologists per million people and in Switzerland >35. 
 Infrastructure  
a) Electrophysiology Procedures Across ESC member countries, a median of 1.5 (IQR 
0.9 to 2.1)  hospitals per million people reported performing electrophysiology 
procedures in the 2018/19 survey, ranging from <0.5 hospitals per million in 
Kyrgyzstan, Romania, Ukraine, Azerbaijan and Egypt to >3 in Ireland, Germany, 
Belgium Italy and France. Republic of Kosovo was an outlier in reporting no 
hospitals performing electrophysiology procedures. 
b) Pacemakers and other devices  The 2018/19 survey of ESC member countries 
recorded a median of 3.5 (IQR 1.7 to 5.0) hospitals per million people implanting 
pacemakers, 1.8 (IQR 1.2 to 3.2) implanting implantable cardioverter defibrillators 
and 1.6 (IQR 1.0-2.7) implanting cardiac resynchronisation therapy pacemakers . 
Generally speaking it was middle income countries where the density of hospitals 
performing device implantation procedures was low (FIGURE 7.13). Pacemakers, 
for example, were implanted in <1 hospital per million people in Ukraine, Republic 
of Moldova, Kyrgyzstan, Azerbaijan and Egypt compared with >7 hospitals per 
million people in Italy, Austria, Switzerland and Belgium. In Germany 13.5 hospitals 
per million people performed pacemaker implantations (FIGURE 7.14, FIGURE 
S7.9). 
 Service Delivery  
a) Diagnostic Electrophysiology Procedures A median of 106.8 (IQR: 49.5 to 320.4) 
diagnostic electrophysiology procedures per million inhabitants of ESC member 
countries were reported in the 2018/19 survey (FIGURE 7.15). Rates ranged from fewer 
than 20 procedures per million people in Republic of Moldova, Albania and Kyrgyzstan 
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to more than 500 in Croatia and Sweden. In Czech Republic 957.8 diagnostic 
electrophysiology procedures per million people were carried out in 2016 but in 
Republic of Kosovo none was performed (FIGURE S7.10). 
b) Ablation Procedures A median of 287.1 (IQR 69.0 to 474.0) ablation procedures per 
million inhabitants of ESC member countries were performed for treatment of cardiac 
arrhythmias (FIGURE 7.16). Rates ranged from <15 procedures per million people in 
Republic of Moldova, Kyrgyzstan and Albania to >600 in Czech Republic, Belgium, 
Norway, Denmark and Switzerland. In Germany 980 ablation procedures per million 
people were carried out in 2016 but in Republic of Kosovo none was performed (FIGURE 
S7.11). 
c) Pacemaker Implants A median of 694.1 (IQR 238.1 to 860.7) pacemaker implants per 
million inhabitants of ESC member countries were reported in the 2018/19 survey 
(FIGURE 7.17, FIGURE S7.12) Rates ranged from <60 implants per million people in 
Republic of Kosovo, Azerbaijan, Egypt and Kyrgyzstan to >1000 per million people in 
France, Belgium, Italy, Portugal, Finland and Germany. 
d) Implantable Cardioverter Defibrillator (ICD) Implants A median of 100.2 (IQR 21.5 to 
150.8) ICD implants per million inhabitants of ESC member countries were reported in 
the 2018/19 survey (FIGURE 7.18).  Rates ranged from <5 implants per million people 
in Azerbaijan, Egypt, Republic of Moldova, Ukraine and Kyrgyzstan to more than 300 
per million people in Netherlands, Germany and Czech Republic (FIGURE S7.13). 
e) Cardiac Resynchronisation Therapy Pacemaker (CRT-P) Implants A median of 24.1 (IQR 
4.8 to 41.6) CRT-P implants per million inhabitants of ESC member countries were 
reported in the 2018/19 survey (FIGURE 7.19). Rates ranged from <2 implants per 
million people in Russian Federation, Ukraine, Republic of Kosovo, Kazakhstan, 
Kyrgyzstan and Azerbaijan to >50 per million people in Iceland, France, United Kingdom, 
Sweden and Denmark. Republic of Moldova was the only ESC member country 
reporting no CRT-P implants (FIGURE S7.14). 
f) Cardiac Resynchronisation Therapy Defibrillator (CRT-D) Implants A median of 43.2 
(IQR 8.0 to 89.3) CRT-D implants per million inhabitants of ESC member countries were 
reported in the 2018/19 survey (FIGURE 7.20). Rates ranged from <2 implants per 
million people in Republic of Kosovo, Albania, Ukraine and Kyrgyzstan to >150 per 
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million in Israel, Czech Republic, Italy and Germany. Republic of Moldova was the only 
ESC member country reporting no CRT-D implants (FIGURE S7.15). 
 Stratification by National Income Status  The 2018/19 survey showed that, compared with 
high income ESC member countries, the median number of electrophysiologists per million 
inhabitants of middle income countries was lower (1.6 (IQR 0.8 to 2.3) vs 5.1 (IQR 4.0 to 
10.5) (FIGURE 7.21), and fewer hospitals per million people were performing 
electrophysiological procedures (0.6 (IQR 0.4 to 1.0 vs 1.8 (IQR 1.2 to 2.5)) (FIGURE 7.22) 
and pacemaker implantations (1.4 (IQR 0.9 to 2.3) vs 4.3 (IQR 3.5 to 6.4)) (FIGURE 7.23). 
Accordingly the median number of procedures per million people was lower in middle 
income countries where fewer ablation procedures for treatment of cardiac arrhythmias 
were performed (59.9 (IQR 16.6 to 145.9) vs 402.7 (IQR 309.4 to 538.1)) (FIGURE 7.24) and 
fewer pacemakers (125.7 (IQR 64.3 to 252.6) vs 794.1 (IQR 697.7 to 932.0)), ICDs (10.1 (IQR 
4.5 to 27.2) vs 133.5 (IQR 102.7 to 206.9)) (FIGURE 7.25) CRT-Ps (3.1 (IQR 1.7 to 6.3) vs 
34.2 (IQR 24.1 to 45.8)) (FIGURE 7.26) and CRT-Ds (4.0 (IQR 1.1 to 9.3) vs 68.1 (IQR 48.6 to 
100.0)) (FIGURE 7.27) were implanted. Concealed within these averaged data, however, 
were many outliers, and among middle income ESC member countries, for example, 
Bulgaria and Serbia competed with many high income countries for the number of 
pacemakers they implanted while Turkey competed for the number of ICDs it implanted. 
Conversely, under-performing high income countries with device implantation rates per 
million people comparable to many middle income countries include Cyprus for 




7.4.1 Coronary Surgery  
Data:  
Data source:  
Completeness:  
Year of data: 
 
 Human Resource The 2018/19 survey identified a median of 6.8 (IQR 4.9 to 11.4) cardiac 
surgeons per million people working in ESC member countries (FIGURE 28). Numbers 
ranged from <3 surgeons per million in Republic of Kosovo, Armenia, North Macedonia, 
Azerbaijan and Kyrgyzstan to >15 per million in Denmark, Finland, Italy, Lithuania and 
Switzerland. Greece reported 35.3 cardiac surgeons per million people (FIGURE S7.16). 
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 Infrastructure A median of 1.3 (IQR 0.9 to 1.7) hospitals per million inhabitants of ESC 
member countries were reported to have facilities for cardiac surgery in the 2018/19 
survey, ranging from <0.7 hospitals in Kyrgyzstan, UK, Republic of Moldova, Slovak 
Republic, Latvia and Ukraine to >2.3 in Greece, Belgium, Republic of Georgia, Iceland and 
Turkey (FIGURE 29, FIGURE S7.17). 
 Service Delivery  A median of  301.1 (IQR 245.0 to 440.0) coronary artery bypass graft 
(CABG)  procedures per million inhabitants of ESC member countries were reported in the 
2018/19 survey (FIGURE 30). Rates ranged from <100 CABG procedures per million people 
in Ukraine, Kyrgyzstan, and Republics of Moldova and Kosovo to >500 in Serbia, Turkey, 
Lithuania, Slovenia, Belgium, Croatia and Netherlands (FIG S7.18).  
 Stratification by National Income Status  The 2018/19 survey showed that the median 
number of cardiac surgeons per million inhabitants was lower in middle income countries 
(4.5 (IQR 2.7 to 6.0)) compared with high income countries 8.2 (IQR 6.7 to 13.4)) (FIGURE 
7.31) although there was little difference in the median number of hospitals with cardiac 
surgical facilities (1.3 (IQR 0.9 to 1.5) vs 1.2 (IQR 0.9 to 1.6)) or the median number of CABG 
procedures per million inhabitants (263.0 (IQR 82.8 to 442.0) vs 324.2(IQR 254.8 to 433.9)) 
(FIGURE S7.19). These averaged data concealed considerable variation with Republic of 
Georgia, Bulgaria, Serbia and Turkey among middle income countries reporting over 400 
procedures per million people per year, thereby outperforming all but 8 of the high income 
ESC member countries.  
 
 
7.4.2  Transplant  Surgery and LVADs 
Data:  
Data source:  
Completeness:  
Year of data: 
 
 Infrastructure Fourteen ESC member countries reported no hospitals with heart transplant 
programmes in the 2018/19 survey and the median number among all countries was 0.18 
(IQR 0 to 0.4) hospitals per million inhabitants. Only Latvia, Belgium, Germany Lithuania 
and Malta reported more than 0.5 hospitals per million inhabitants with transplant 
programmes (FIGURE 7.32). 
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 Service Delivery Across ESC member countries, a median of 2.1 (IQR 0 to 5.2)  hospitals 
per million people reported performing heart transplantation procedures in the 2018/19 
survey. Rates ranged from <2 transplants per million people per year in Latvia and Greece 
to >10 in Czech Republic and Slovenia. The variation in LVAD implants was even greater 
with 11 ESC member countries reporting none while the average among all countries was 
2.7±4.2 per million people per year, ranging from <1.5 in Serbia, Kyrgyzstan, Egypt, Poland, 
Hungary, UK and Greece to >5.0 in Croatia, Germany, Slovenia and Lithuania. 
 Stratification by National Income Status ESC member countries without transplant 
programmes in the 2018/19 survey were predominately middle income and included 
Albania, Azerbaijan, Bosnia and Herzegovina, Egypt, Kyrgyzstan, Republic of Georgia, 
Republic of Kosovo, Republic of Moldova, TFYR Macedonia and Ukraine (FIGURE 33). 
Among high income countries only Cyprus, Iceland and Luxembourg were without 
transplant programmes. Transplant activity was generally greater in high income countries 
where a median of 4.6 (IQR 2.3 to 6.0) procedures were reported in the 2018/19 survey 
ranging from <2.5 in Malta, Netherlands, Latvia and Greece to >7 in France, Croatia, Czech 
Republic and Slovenia. In those middle income countries reporting transplant programmes 
(Romania, Bulgaria, Serbia, Turkey and Kazakhstan) <0.9 procedures per million people 
were undertaken. Similar inequality characterised LVAD implantation which was reported 
in all but three high income countries (Malta, Iceland, Cyprus) rates ranging from <1.5 
procedures per million people in Poland, Hungary, UK and Greece to >8 in Slovenia, 
Germany and Croatia. Among middle income countries only Egypt, Kyrgyzstan, Serbia and  
Kazakhstan reported LVAD implantation but rates were never >1.8 procedures per million 
people.   
 
7.5 Congenital Heart disease   
Data:  
Data source:  
Completeness:  
Year of data: 
 
 Infrastructure A median of 0.5 (IQR 0.3 to 1.0) and 0.4 (IQR 0.3 to 0.7) hospitals per million 
inhabitants of ESC member countries reported performing percutaneous and surgical 
procedures for treatment of congenital heart disease in the 2018/19 survey (FIGURE 7.34). 
Numbers ranged from <0.2 hospitals per million people undertaking percutaneous 
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procedures in Norway and Finland to >2.0 in Malta, Italy and Iceland and from <0.2 
hospitals per million people undertaking surgical procedures in Norway, Greece, Finland 
and France to >2.0 in Malta, Kazakhstan and Iceland (FIGURE S7.20). Only Republic of 
Kosovo among ESC member countries reported no hospitals performing percutaneous or 
surgical treatment of congenital heart disease . 
 Service Delivery Across ESC member countries, a median of 26.0 (IQR 13.4 to 39.7) 
percutaneous procedures and 49.4 (IQR 22.4 to 69.8) surgical  procedures for congenital 
heart disease were reported in the 2018/19 survey (FIGURE 7.35).   Rates ranged from <10 
percutaneous procedures per million people per year in Romania, Albania, Kyrgyzstan, 
Azerbaijan, Bosnia and Herzegovina and Armenia to >90 in Switzerland, Croatia and Iceland 
and from <10 surgical procedures per million people per year in Malta and Sweden to >100 
in Republic of Moldova, Lithuania, Israel and Kazakhstan. (FIGURE S7.21) 
 Stratification by National Income Status In comparing middle income and high income 
countries, the median number of hospitals per million people providing percutaneous (0.6 
(IQR 0.3 to 0.9)  vs 0.5 (IQR 0.4 to 1.1)) and surgical (0.6 (IQR 0.4 to 0.8) vs 0.3 (IQR 0.2 to 
0.6)) procedures for treatment of congenital heart disease were similar (FIGURE S7.22). 
TFYR Macedonia and Albania, for example, reported almost identical numbers offering 
percutaneous treatment as Austria and Luxembourg while Kazakhstan competed with 
Iceland for the most hospitals per million people offering surgical treatment. Nevertheless, 
the median number of procedures per million inhabitants was lower in middle income 
compared with high income ESC member particularly for percutaneous interventional 




 Huge variation in cardiological person-power across ESC member countries likely 
reflects under-provision in many countries although definitions of what constitutes a 
cardiologist may also vary. 
 
 Compared with high income countries, middle income countries are severely under-
resourced in terms of cardiological person-power and technological infrastructure 
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 The under-resourced status of middle income countries is associated with a severe 
procedural deficit compared with high income countries in terms of coronary 
intervention, device implantation and cardiac surgical procedures. 
 
 While many middle income countries are under-resourced in terms of cardiological 
person-power, infrastructure and procedure rates, outliers can often be identified 
emphasising that national income status is not the only driver for cardiological 
healthcare delivery 
 
7.7 Commentary  
The 2018/19 survey of ESC member countries shows continuing heterogeneity in cardiological 
specialist provision, hospital facilities and healthcare delivery that likely contribute to the 
inequalities in cardiovascular outcomes documented elsewhere in this report. There is no 
clear consensus about what constitutes optimal specialist provision but the 15-fold variation 
in cardiologists per million people across ESC member countries suggests that definitions of 
what constitutes a cardiologist may vary and that under-provision may be common with 
potentially deleterious effects on cardiovascular outcomes. Certainly there is considerable 
evidence that outcomes in patients with cardiovascular disease are more favourable when 
clinical management involves  a specialist cardiologist and this is reflected in contemporary 
quality indicators.89 90 Moreover, there are now data showing that patients hospitalized for 
myocardial infarction and heart failure in those US regions that have a high density of 
cardiologists experience lower 30-day and 1-year mortality, compared with patients 
hospitalised in regions with a low density of cardiologists.91 The under-provision of 
cardiologists in many ESC member countries is compounded by under-representation of 
women which is now recognised as a particular problem for cardiology as it affects diversity 
within the specialty.92 93 Reasons for the under-representation of women are complex but 
need correction in order that the benefits of a more diversified work force can be realised.  
 
Heterogeneity of capital resources was a major finding of the 2018/19 survey with a tendency 
for fewer hospitals per million people offering facilities for treatment of coronary disease, 
structural heart disease and electrophysiological disorders in middle income compared with 
high income ESC member countries. There was similar inequality in rates of interventional 
procedures, no doubt driven in part by their collective expense, with new technology a key 
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contributor to the spiralling costs of contemporary healthcare.88 For some of these 
programmes costs are expected to rise further, with potential  candidates for TAVR in the 
European Union, for example, on a steep upward trajectory as indications expand to include 
patients at low surgical risk.94 ICD treatment is also on an upward trajectory, but remains 
severely under-utilized across Europe.95 Substantial growth in ICD implantations is expected 
in future years as the divergence between its utilisation compared with the US is corrected. 
These changes in interventional and device treatments of cardiovascular disease are likely to 
have major implications for health care costs in ESC member countries.  
 
The data in our report indicate that national economic resource is not the only driver for 
delivery of equitable cardiovascular healthcare across ESC member countries. Thus, in some 
middle income countries, rates for interventional procedures and device implantations match 
or exceed rates in wealthier high income countries. Even within high income countries the 
2018/19 survey identified substantial differences in procedure rates, with ICD implantations 
per million people, for example, varying 7-fold between Lithuania and Czech Republic. 
Explanations for these inequalities may need to look beyond economic resource at 
differences in the national priorities given to healthcare and differences in the way in which 
healthcare systems are funded. Healthcare expenditure per capita in the US, for example, is 
higher than in England, yet the ways in which expenditure is allocated are very different and 
contribute to better outcomes for cardiac revascularisation in the UK despite lower costs.96  
 
The WHO’s global targets on prevention and control of noncommunicable diseases  provide 
interesting context to the CVD healthcare needs of the ESC member countries.4 The ninth 
global target calls for an 80% availability of the affordable basic technologies and essential 
medicines, including generics, required to treat major noncommunicable diseases. Basic 
essential technologies are defined as a blood pressure measurement device, a weighing scale, 
height measuring equipment, blood sugar and blood cholesterol measurement devices with 
strips, and urine strips for albumin assay. It is reasonable to assume that this target has long 
been achieved by ESC member countries none of which meet World Bank low income criteria. 
Yet the fact that low income countries elsewhere in the world fail to meet this target, despite 
an increasing prevalence of CVD, puts into context the technological shortfalls of middle 
income ESC member countries identified in the 2018/19 survey. This is not to say these 
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shortfalls are not in need of correction but it is a reminder of how much further the low 
income countries of the world have to go in combating the emerging CVD epidemics they now 
are facing. 
 
The paradox of greater cardiological provision in those high income ESC member countries 
where need is manifestly provides an exemplar of Tudor Hart’s inverse care law 3 and together 
with inequalities in hypertension and smoking must contribute to the continued imbalance in 
cardiovascular mortality between high and middle income member countries. Resolution of 
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